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Takotsubo syndrome (TTS) is a severe acute heart disease presumably caused by high 
catecholamine levels resulting in wall motion abnormalities of the left ventricle. Despite 
the severe phenotype of TTS, the exact disease mechanisms remain elusive. This project 
aims to model TTS with the help of induced pluripotent stem cell (iPSC) derived 
cardiomyocytes (iPSC-CMs) on a patient-specific level. To achieve this goal, 4 TTS 
patients and 3 control probands were recruited. Human fibroblasts or peripheral blood 
mononuclear cells (PBMCs) were reprogrammed to iPSCs using integration-free 
methods. The resulting iPSCs exhibited typical iPSC-morphology and expressed specific 
pluripotency-related genes on messenger RNA (mRNA) and protein level. The cells could 
be readily differentiated into cells from all three different germ-layers in vitro and in vivo. 
IPSCs were successfully differentiated to iPSC-CMs with purity over 80 % and expressing 
cardiac markers like cTnT and α-actinin. 
To mimic a TTS event, iPSC-CMs were treated with increasing concentrations of 
catecholamines such as epinephrine (Epi) or isoproterenol (Iso). The used high 
catecholamine levels did not induce significant levels of apoptosis, therefore excluding 
acute cytotoxicity. To test electrophysiological outcomes in the iPSC-CMs, beating rate 
and regularity were analyzed by using the multi-electrode array (MEA) system. MEA 
measurements uncovered electrical stunning for iPSC-CMs stimulated with rising levels 
of catecholamines. TTS-iPSC-CMs were more vulnerable to this effect. The remaining 
TTS-iPSC-CMs showed a stronger frequency increase when stimulated with Iso than 
CTRL-iPSC-CMs. 
Functioning calcium (Ca2+) cycling is of utmost importance in cardiomyocytes since Ca2+ 
is a key player in excitation-contraction coupling and Ca2+ abnormalities are involved in 
many heart diseases. TTS-iPSC-CMs demonstrated differences in Ca2+ cycling compared 
to CTRL-iPSC-CMs on multiple levels: Under basal conditions and after Iso stimulation, 




comparison to CTRL-iPSC-CMs. CTRL-iPSC-CMs showed a higher spark frequency at 
higher Iso levels (1 µM), but overall, there was no difference in total Ca2+ leakage. 
To analyze TTS on the tissue level, engineered heart muscles (EHM) were generated and 
used as a 3D-model. When challenged with Iso, the TTS-iPSC-EHMs showed a 
significantly higher sensitivity compared to CTRL-iPSC-EHMs as shown by a lower half-
maximal effective concentration (EC50). After 24 h Iso pre-stimulation, the CTRL-iPSC-
EHMs exhibiting a stronger EC50 increase than TTS-iPSC-EHM, thereby exhibiting 
stronger receptor desensitization. Additionally, beating frequency changes after 24 h Iso 
stimulation were higher in TTS-iPSC-EHM compared to CTRL-iPSC-EHM, which is in line 
with the reported frequency differences in the 2D MEA measurements. Interestingly, TTS-
iPSC-EHM showed a lower force development than CTRL-iPSC-EHM without 
catecholamine stimulation.  
Since adrenergic stimulation results in positive inotropic and chronotropic effects of the 
heart and thereby regulates lipid metabolism in cardiomyocytes, lipid droplets were 
quantified using Oil Red O. The TTS-iPSC-CMs exhibited higher lipid accumulation in 
comparison to CTRL-iPSC-CMs, suggesting a role of lipotoxicity in the disease. 
The selective β-adrenergic receptor (β-AR) blockers CGP (β1-AR blocker) and ICI (β2-
AR blocker) were used to uncover the roles of different β-ARs in CTRL- and TTS-iPSC-
CMs. In CTRL-iPSC-CMs, β2-AR blocker alone was enough to reduce an Iso-dependent 
frequency increase and an Iso-dependent T50 and rise time decrease, thus underpinning 
the role of the β2-ARs in CTRL-iPSC-CMs. In TTS-iPSC-CMs, β1-AR blockage abolished 
Iso-dependent T50 and rise time reduction, which was not the case for β2-AR blockers 
and therefore underpins an important role of β1-AR in TTS-iPSC-CMs.  
In conclusion, these results demonstrate that CTRL- and TTS-iPSC-CMs behave 
differently with respect to catecholamine sensitivity, Ca2+ handling, lipid accumulation, 
electrophysiology, and β-AR preferences. This behavior hints towards a genetic 
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1.1 Takotsubo syndrome 
 
1.1.1 Clinical presentation of Takotsubo syndrome 
 
Takotsubo syndrome is a recently described severe cardiac disease. It was first described 
in Japan in 1990 by Sato (Sato, 1990). Initially, only described in Japan, it was soon shown 
to be present worldwide (Desmet et al., 2003; Wittstein et al., 2005). Since then, it has 
become a more and more recognized cardiac health problem (Ghadri et al., 2018a). 
Typically, TTS is triggered by emotional or physical stress and is most prevalent in elderly 
women. It is characterized by left ventricular wall motion abnormalities of transient nature 
(Hurst et al., 2010; Templin et al., 2015). In 82% of cases, the apical part of the left 
ventricle shows prominent dyskinesia and the basal parts of the ventricle show 
hyperkinesia (Templin et al., 2015). Additionally, there are some more uncommon 
representations of TTS with basal hypokinesia or medial hypokinesia described (Templin 
et al., 2015). The wall motion abnormalities give rise to the typical ventricular shape in 
TTS, showing apical ballooning. This very unique form reminded the first describers in 
Japan of a Takotsubo, a Japanese octopus trap with a shape similar to the typical TTS 
ventricle (Sato, 1990). The prevalence of TTS is not exactly known. However, TTS was 
diagnosed in about 2% of acute coronary syndrome suspect cases (Gianni et al., 2006), 
making up to 0.02% of overall hospitalization in the USA (Deshmukh et al., 2012). 
To explain the underlying pathophysiology in TTS, many theories have been developed. 
Most of them agree upon the causative nature of high catecholamine levels in patients. 
Indeed, Wittstein et al. quantified the levels of catecholamines in TTS and MI patients and 
were able to show that the levels in TTS were at least twice as high in TTS than in MI 
(Wittstein et al., 2005). Furthermore, there are case reports where TTS is triggered after 
iatrogenic epinephrine (Epi) injection (Geppert et al., 2010; Zubrinich et al., 2008). TTS 
triggered by pheochromocytoma, a catecholamine-producing tumor, is another piece of 
evidence towards catecholamines as the leading cause of TTS (Kim et al., 2010; Schmidt 




catecholamines by sympathetic neurons was shown to be increased in 5 TTS cases 
analyzed by Kume and colleagues (Kume et al., 2008). Notably, while catecholamines are 
the widest accepted explanation, β-blockers were not necessarily protecting patients from 
recurrent TTS attacks (Isogai et al., 2016; Sharkey et al., 2010). However, Ueyama and 
colleagues were able to readily prevent apical ballooning by beta-blocker pre-treatment in 
a rat model of TTS (Ueyama et al., 2002). Izumi et al. could provoke a TTS-like phenotype 
in cynomolgus monkey by Epi injection and were able to ameliorate the phenotype by 
using a one-time injection of the beta-blocker metoprolol (Izumi et al., 2009). 
The wall motion abnormalities cause a significant drop in cardiac ejection fraction, which 
can be life-threatening. In consequence, patients suffer from dyspnea and chest pain and 
exhibit cardiac damage marker elevations including troponin and brain natriuretic peptide 
(Templin et al., 2015). Additionally, ST-segment elevation in the electrocardiogram (ECG) 
was on a similar level, as observed in myocardial infarction (MI) (Ghadri et al., 2018a; 
Templin et al., 2015). Moreover, additional ECG abnormalities such as ST-segment 
depression, T-wave inversion, and QTc prolongation can be present (Ghadri et al., 
2018a). After the sudden onset of symptoms, the wall motion abnormalities recover over 
time without additional intervention (Templin et al., 2015). This might contribute to the fact 
that briefly after its first description, TTS outcome was considered mild (Prasad et al., 
2008). However, the opposite is actually true: very severe complication as ventricular 
thrombi (Icli et al., 2016), ventricular rupture (Jaguszewski et al., 2012), left ventricular 
outflow tract obstruction (El Mahmoud et al., 2008), pulmonary edema (Bharathi et al., 
2016), cardiogenic shock (Templin et al., 2015) and life-threatening arrhythmias 
(Stiermaier et al., 2015) can occur in TTS patients and demand for their close observation 
during hospitalization until full recovery (Ghadri et al., 2018b). The recently observed in-
hospital mortality rate of TTS from 3.7% (Templin et al., 2015) to 4.2% (Brinjikji et al., 
2012) is comparable to that of MI with around 5% (Templin et al., 2015). It is of note that 
while men are less likely to develop TTS, they harbor a significantly higher risk of in-
hospital death of 8.4% (Brinjikji et al., 2012). Unfortunately, after recovery from TTS, 
additional TTS attacks may occur with a probability of 1.8% per patient-year (Templin et 
al., 2015) or 5% overall in other studies (Sharkey et al., 2010), suggesting a certain 




the long-term mortality (Stiermaier et al., 2016; Tornvall et al., 2016) and adverse 
cardiovascular event rates are as high as in patients who survived a MI (Templin et al., 
2015).  
Until today, there is no targeted treatment of TTS available as prospective randomized 
clinical trials are missing (Ghadri et al., 2018b). Therefore, TTS is mainly treated like acute 
coronary syndrome (Ghadri et al., 2018b). Patients are administered aspirin, heparin, β-
blockers, diuretics, nitroglycerin, and angiotensin-converting enzyme (ACE) inhibitors 
while being monitored closely (Ghadri et al., 2018b; Sharkey et al., 2010). Additional, non-
conventional drugs like the Ca2+ sensitizer levosimendan have been used in a small study 
(Santoro et al., 2013). In some cases, pacing devices become necessary to counteract 
arrhythmias (Ghadri et al., 2018b; Peters and Klein, 2012). Therefore, TTS is a severe 
cardiac disease and needs intensive research to find out the underlying pathology 
mechanisms and potentially helpful drugs. 
The aforementioned clinical features were making it hard to distinguish TTS from MIs and 
thus going in line with the late description of the disease. Importantly, in contrast to a MI, 
there is no coronary vessel occlusion present in TTS. Consequently, a MI is ruled out 
during TTS diagnostics via coronary angiography with left ventriculography. To improve 
the diagnostic procedure of TTS, the Mayo Clinic criteria (Prasad et al., 2008) have been 
developed, which include several criteria to define TTS: transient wall motion 
abnormalities, which reach beyond the territory of a single coronary artery, the presence 
of new electrical abnormalities and absence of a coronary artery occlusion or plaque 
rupture (Prasad et al., 2008). Since then, many more diagnostic catalogs have been 
published, which include the possible coexistence of neurologic disorders (Ghadri et al., 
2018a). Lately, a set of circulating micro RNAs (miRNA), namely miR-1, miR-16, miR-26a 
and miR-133a, have been found to differentiate TTS from healthy controls and ST-
segment elevation myocardial infarction (STEMI) patients. Unfortunately, the specificity 
was only around 70%. However, this approach may help in the diagnostic procedure of 





1.1.2 Trigger of Takotsubo attacks 
 
The cause of TTS remained elusive for some time. The link towards catecholamines was 
established by observing typical triggers for TTS. A link between TTS and stressful events 
such as natural disasters or the death of a loved one was observed in about 27% of TTS 
cases (Templin et al., 2015), giving the disease the nickname broken heart syndrome to 
reflect this. Consequently, after connecting TTS to stressful events, researchers found 
immensely increased catecholamine levels in patients with TTS (Wittstein et al., 2005). 
Interestingly, 28.5% of TTS cases show no obvious trigger (Templin et al., 2015). Notably, 
TTS is not only triggered by stressful emotional events, but it is also triggered by physical 
injury, mainly brain injury, which accounts for 36% of the TTS cases, with one prominent 
example being subarachnoid hemorrhage (Templin et al., 2015). In addition, stroke has 
been reported to trigger TTS (Blanc et al., 2015; Scheitz et al., 2012). Furthermore, 7.7% 
of subarachnoid hemorrhage patients also developed TTS in a patient collective of 371 
patients (Inamasu et al., 2016). There is also a strong connection between TTS and 
epilepsy and it is thought that TTS is indeed responsible for a fraction of sudden cardiac 
deaths in epilepsy patients (Dupuis et al., 2012). Generally, TTS has a strong correlation 
with neurologic (27%) and psychiatric disorders (42%), emphasizing the role of the heart-
brain axis in the disease (Templin et al., 2015; Hiestand et al., 2018). Indeed, anxiety was 
significantly more present in a TTS patient collective compared to a STEMI collective or 
neutral patient collective analyzed by Summers et al. (Summers et al., 2010). An 
investigation by Delmas et al. yielded similar results: TTS patients showed more anxio-
depressive disorders and chronic psychological stress than acute myocardial syndrome 
patients (Delmas et al., 2013). The connection between TTS and neuropsychiatric 
disorders, which clearly increase the TTS risk, is currently under intensive studies and 
demonstrates that the brain indeed has a strong influence on the heart as also shown for 
MI, which is more likely to occur in patients suffering from depression (Wu and Kling, 
2016). 
 





TTS is most common in postmenopausal women, with 89.8% of patients being women 
overall (Templin et al., 2015). The increased vulnerability of these particular groups gave 
rise to the theory that estrogen does not only play a role but could be protective against 
TTS (Ueyama et al., 2003). Estrogens have been shown to influence vasomotor activity 
by influencing NO levels (Sader, 2002). Moreover, estrogen reduced catecholamine 
responses in perimenopausal women (Komesaroff et al., 1999). In the setting of 
subarachnoid hemorrhage in women, low estrogen levels were associated with cardiac 
wall motion disturbances (Sugimoto et al., 2012). Additionally, Ueyama and colleagues 
showed that estrogen ameliorated TTS in a model of ovariectomized rats (Ueyama et al., 
2003). El-Battrawy and colleagues demonstrated in an iPSC-CM model that estradiol 
suppressed a catecholamine-caused action potential duration prolongation and reduced 
a catecholamine-based reactive oxygen species (ROS) production (El-Battrawy et al., 
2018). 
However, not only women but also men fall victim to the disease and the nature of the 
stressful events can be heterogeneous, as indicated by a TTS case of a fan during a 
stressful soccer match (Fijalkowski et al., 2013). Surprisingly, while most people tend to 
experience strong emotional stress at some point in their life, TTS is not regularly 
developed, arguing for an increased vulnerability of a fraction of the population, which 
indicates genetic or epigenetic risk factors. In support of a genetic component of TTS, 
several cases of TTS have been found in one family (Cherian et al., 2007). In support of 
these findings, Tak et al. reported a case of two sisters with TTS (Tak et al., 2018). Ikutomi 
et al. also reported two menopausal sisters with TTS suffering from TTS attacks just one 
year apart (Ikutomi et al., 2014). Another publication also reported TTS in two sisters aging 
44 and 52 (Pison et al., 2004). The striking common ground of two sisters is logical given 
the age and gender distribution of TTS and its relatively recent discovery. Following the 
rationale of familial TTS cases, some groups found single nucleotide polymorphisms 
(SNPs), which are associated with TTS. An interesting SNP, which was found in the 
protein BAG3, inhibits the binding of BAG3 mRNA to the activating miRNA-371 (d’Avenia 
et al., 2015). This causes a reduction in BAG3 levels making the cells more prone to 
stressful events such as catecholamine flooding. Another of these SNPs is located in the 




catecholaminergic β-AR (Spinelli et al., 2010). Further research into β-AR signaling was 
done by Sharkey et al., who analyzed different mutations in β-ARs in TTS patients and 
found no differences between patients and healthy controls (Sharkey et al., 2009). 
Researching the interplay between β-ARs, subarachnoid hemorrhage and cardiac injury 
and dysfunction, Zaroff and colleagues found that the (Arg/Arg) combination of β1-AR 
Arg389Gly SNP in combination with α2-AR deletion at amino acid positions 322–325 had 
a higher likelihood of reduced ejection fractions in observed patients (Zaroff et al., 2006). 
Another study compared β-AR variants between 61 TTS and 109 control cases and found 
a higher frequency of the same β1-variant at amino acid position 389 as Zaroff et al. and 
a lower occurrence of Gln/Gln at the β2-variant at amino acid position 27 in TTS (Vriz et 
al., 2011). A study from 2018 discovered heterogenous copy number variants of RBFOX1, 
GPC5, KCNRG, CHODL and GPBP1L1 in TTS cases (Lacey et al., 2018). Underpinning 
the heterogeneous nature of the SNPs found, some of these studies contradicted the 
findings of GRK5 and BAG3 polymorphisms in TTS (Figtree et al., 2013; Mattsson et al., 
2018). Additionally, all studies have a relatively small sample size and therefore offer only 
limited insight. In summary, none of the discovered SNPs can fully explain all TTS cases. 
However, the number of SNPs found and familial clustering of some cases suggest a 
genetic component contributing to the pathogenesis of TTS. 
One interesting factor in TTS is the epigenetic influence. It was shown that withdrawal of 
estrogen causes epigenetic changes (Zhao et al., 2010), which could, in theory, be a risk 
factor for the disease. Estrogen also has regulatory roles in catecholamine release and 
catecholamine effects in cardiomyocytes (Bupha-Intr and Wattanapermpool, 2006; Eskin 
et al., 2003; Li et al., 2000a; Ranki et al., 2001).  
Notably, TTS patients have been recently associated with a high prevalence of malignant 
diseases (Girardey et al., 2016; Sattler et al., 2017, 2018). Therefore, it was already 
speculated that both diseases might be connected to a common source, which could be 
catecholamine excess (Sattler et al., 2018). This could very well contribute to the negative 





1.1.4 A variety of hypotheses try to explain the TTS phenotype 
 
While high serum-level of catecholamines may trigger different disease entities, the exact 
mechanisms of how exposure to excessive catecholamine levels cause a TTS attack is 
widely unknown. Animal models and observations in patients have led to several theories. 
As the wall motion abnormalities are not localized in an area nourished by one coronary 
artery, the occlusion of such a large vessel is unlikely to be the underlying cause. 
However, some groups think that microvascular spasms could cause such wall motion 
abnormalities (Galiuto et al., 2010). Galiuto and colleagues showed that adenosine 
injection during acute TTS events improved ventricular wall motion, thereby suggesting 
the involvement of microvascular vasoconstriction in the TTS etiology (Galiuto et al., 
2010). Furthermore,  slow coronary blood flow was observed in several TTS cases 
(Abdelmoneim et al., 2009; Vitale et al., 2016). It was demonstrated that vascular spasms 
can be caused by emotional stress (Lacy et al., 1995), which is also a major trigger of 
TTS. Another approach towards a vascular explanation was undertaken by Uchida et al., 
observing increased apoptosis in endothelial cells in individuals with TTS (Uchida et al., 
2010). Additionally,  endothelin-1 was found to be increased in TTS (Jaguszewski et al., 
2014). Furthermore, endothelin-1 was found to cause vasoconstriction at high levels 
(Kiowski et al., 1991). 
Paur et al. suggested a prominent role of the β2-AR in TTS and provided evidence in a 
sophisticated mouse model. They postulate a switch from an activating Gs protein to an 
inhibiting Gi protein triggered by high catecholamines levels (Paur et al., 2012). They also 
state that the β2-ARs are more prominent in the apical part of the heart compared to the 
basal part, thereby explaining the specific shape of a TTS ventricle (Paur et al., 2012). To 
trigger TTS, Paur et al. injected a high bolus dosage of catecholamines into wildtype rats 
and found their ventricular function decreased. TTX, a blocker for Gi signaling, was able 
to ameliorate this effect (Paur et al., 2012). It is of note that physiological studies in dogs 
found higher levels of norepinephrine in the basal part and less in the apical part of the 




line with Paur et al., Heubach and colleagues demonstrated that Epi activated Gs and Gi 
proteins in mice hearts (Heubach et al., 2004). 
Other groups including Shao et al. suggested that lipotoxicity might play a major role in 
the pathophysiology and show a strong lipid accumulation in their mouse model where 
they injected high dosages of catecholamines into the mice (Shao et al., 2013). 
Furthermore, the lipid transporters and lipid-associated proteins were different in 
catecholamine-treated mice compared to untreated mice. They also showed that TTS 
patient serum alone is sufficient to suppress the electrical activity of cardiomyocytes in 
vitro (Shao et al., 2013). This last finding, in part, contradicts the microvascular spasm 
theory as the sole pathophysiological mechanism as the cardiomyocyte suppression also 
worked in vitro without any vessels. 
Additionally, oxidative stress might play a role in TTS. In this regard, Zhang et al. showed 
that H2S can be protective in a TTS rat model by reducing NAPD oxidase and, ultimately, 
ROS production (Zhang et al., 2017). Additionally, in an iPSC-CM setting, Iso 
concentrations of 1 mM were able to induce increased ROS production in the observed 
cells (El-Battrawy et al., 2018). 
 
1.2 Cardiac physiology 
 





To understand TTS, it is important to investigate human cardiac physiology. In the heart, 
cardiac cells receive an action potential from the cardiac conduction system, which causes 
voltage-gated sodium channels to open, causing an influx of sodium ions depolarizing the 
cardiomyocytes (Figure 3). At a certain level of depolarization, voltage-gated L-type 
Ca2+channels are opening while at the same time, the sodium channels are inactivated.  
Figure 1: Normal cardiac physiology in a human cardiomyocyte. Sodium channels are opened 
upon a depolarizing signal and further depolarize the cardiomyocyte, which triggers calcium (Ca2+) 
release from L-type calcium channels. This calcium triggers calcium-induced calcium release 
(CICR) from ryanodine receptor 2 (RyR2) from the sarcoplasmic reticulum (SR), which in turn 
enables contraction. After contraction, calcium is pumped back to the sarcoplasmic reticulum (SR) 
by the SERCA, which is tightly regulated by phospholamban (PLN). Part of the calcium is pumped 
back to extracellular space by the Na+/Ca2+ exchanger (NCX). 
The newly generated Ca2+ influx keeps the cellular action potential at a plateau and 
triggers the calcium-induced release of even more Ca2+ ions by the ryanodine receptor 2 
(RyR2), which is called calcium-induced calcium release (CICR) (Bers, 2002). The 




troponin C. As a consequence, troponin C changes its confirmation and subsequently 
releases myosin. Myosin can then, assisted by ATP, interact with actin to generate a 
power stroke and, therefore, muscle contraction.  
During diastole and after contraction, Ca2+ is pumped back to the sarcoplasmic reticulum 
(SR) by the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) and the 
extracellular space with the help of the Na+/Ca2+ exchanger (NCX) (Figure 3). The 
contraction is terminated by the reduction of Ca2+ levels, while the cell starts to relax. 
During this phase, the cellular potassium channels open and potassium is released to the 
extracellular space, therefore repolarizing the cardiomyocyte (Bers, 2002). 
 




Figure 2: Schematic G-protein signaling in human cardiomyocytes. Activation of β1-, β2-adreno 
receptors causes the activation of activating Gs proteins. These proteins then activate the 
adenylate cyclase (AC). The AC in turn produces cAMP, which then activates protein kinase A 




signaling through inhibition of AC. PDEs cause a breakdown of cAMP and therefore regulate 
cAMP signal strength. β3-ARs additionally activate nitric oxide synthases (NOS) producing nitric 
oxide enabling protein kinase G signaling. The activity level of the β-AR is controlled by the GRK 
proteins, which phosphorylate the receptors. Picture modified from (Lohse Martin J. et al., 2003) 
The process of cardiac contraction is tightly regulated by catecholamines, which are 
activating cellular β1-, β2- and β3-ARs. Catecholamines are released by sympathetic 
neurons in a local way and by the adrenal medulla in a more systemic way. Through this 
system, the brain has a strong influence on the heart. It is known that stroke patients often 
present with systolic and diastolic dysfunction and arrhythmias at least in part caused by 
catecholamine surges (Manea et al., 2015). Arrhythmias can damage the brain, for 
example, by thromboembolism, thereby creating a heart-brain axis (van der Wall and van 
Gilst, 2013). Therefore it is relatable that TTS is often triggered by dysfunction of the brain 
including subarachnoid hemorrhage (Banki et al., 2005). The released catecholamines 
produce a positive inotropic, positive dromotropic, positive chronotropic, positive 
lusitropic, and positive bathmotropic response in the heart (Bers, 2002). The β1- and β2-
ARs release an activating Gs protein, which activates the adenylate cyclase (Figure 2). 
The adenylate cyclase produces cyclic adenosine monophosphate (cAMP). The cAMP 
activates protein kinase A (PKA), which in turn phosphorylates important proteins for 
cellular excitation and contraction like the L-type Ca2+ channel, the ryanodine receptor 
(RyR) and phospholamban (PLN) (Spadari et al., 2018). Normally, PLN inhibits the 
SERCA pump. A Phosphorylation of PLN stops its inhibiting activity and therefore results 
in an increased SERCA activity (Bers, 2002; Li et al., 2000b). The elevated SERCA activity 
causes faster reuptake of Ca2+ into the SR (positive chronotropic) and causes an 
increased loading of the SR with Ca2+, therefore enabling higher Ca2+ releases during 
systole (positive inotropy) (Bers, 2002). β2- and β3-ARs additionally activate Gi proteins, 
which inhibit the AC, therefore suppressing cAMP response (Spadari et al., 2018). β3-ARs 
also activate nitric oxide synthases (NOS), thereby producing nitric oxide (NO), causing 
cGMP production and leading to protein kinase G activation (Cannavo and Koch, 2017; 
Trappanese et al., 2015). Protein kinase G phosphorylates cellular targets like L-type Ca2+ 
channels and seems to be cardioprotective (Cannavo and Koch, 2017). However, of 
cardiac β-ARs, only a minor fraction is made of β3-ARs, giving the β1-ARs and β2-ARs 




To control the activity of the β-ARs, G-protein coupled receptor kinases (GRK) 
phosphorylate the ARs, causing an internalization and shut off the signal. Furthermore, β-
Arrestin is recruited to phosphorylated β-ARs and physically blocks receptor G-protein 
coupling (Fertig and Baillie, 2018; Krupnick and Benovic, 1998). Phosphodiesterases 
(PDE) shut down the cAMP signal by hydrolyzing cAMP and are recruited towards β-ARs 
by β-arrestin (Fertig and Baillie, 2018). 
 
1.3 Pluripotent stem cells 
 
1.3.1 Multipotent stem cells are found in the human body 
 
The prospect of using primary human cells for regeneration and research has always been 
a dream of medical scientists. This dream was out of range for a very long time since 
human cells are not easy to come by and maintain in culture. Stem cell-like cells in the 
human body have long been known. In the human body, these so-called multipotent stem 
cells are critically important to maintain homeostasis by replacing damaged cells. A good 
example of such cells are hematopoietic and gut cells (Takashima et al., 2013). A hallmark 
of these cells is that they can divide indefinitely and produce a certain set of differentiated 
cells, for example, goblet cells (Takashima et al., 2013) or blood cells like erythrocytes 
and immune cells like B-cells or monocytes for bone hematopoietic stem cells (Rodriguez-
Fraticelli et al., 2018). While these cells can be isolated and cultured for some time, they 
only give rise to limited types of cells.  
 
1.3.2 Embryonic stem cells 
 
It is not surprising that in science and medicine, pluripotent or totipotent cells are of special 
interest as they can produce all cells of the body for pluripotent cells or all cells of the body 
and the cells of the extra-embryonal tissue for totipotent cells. Therefore, they are very 
useful for regenerative approaches. However, such cells were hard to obtain for a long 




blastocysts and were able to keep them in culture in an undifferentiated state (Evans and 
Kaufman, 1981). It turned out that these cells gave rise to all cells in the mouse body and 
were therefore regarded as pluripotent (Evans and Kaufman, 1981). They were named 
embryonic stem cells (ESC). Years later, in 1998, human embryonic stem cells (hESCs) 
were isolated by the team of Thomson and co-workers These cells were also pluripotent 
and were used to produce tissues from all three germ-layers (Thomson et al., 1998). Since 
then, hESCs have been used worldwide to create disease models (Halevy and Urbach, 
2014)  of Turner syndrome (Urbach and Benvenisty, 2009), spinal muscular atrophy 
(Wang et al., 2013), Rett syndrome (Li et al., 2013), Huntington’s disease (Lu and 
Palacino, 2013; Ruzo et al., 2018) and the long-QT syndrome (Bellin et al., 2013). They 
have also been used in trials for regenerative medicine including neural (Adler et al., 2019) 
or cardiac regeneration (Chong et al., 2014). Unfortunately, the production of these cells 
goes hand in hand with the destruction of human embryos, which is very controversial 
debated under ethical considerations (Holm, 2015), and their use was therefore limited in 
some countries such as Germany (Kiechle, 2008). 
 
1.3.3 Alternative approaches to pluripotency 
 
To overcome the problems associated with hESCs, researchers were looking for 
alternative sources of pluripotent stem cells in adults. In 2006, Guan et al. were able to 
generate spermatogonial stem cells (SSCs) from mouse testis tissue. These cells were 
pluripotent and could be generated from adult tissue (Guan et al., 2006). They also 
showed that these cells could be differentiated into neurons (Streckfuss-Bömeke et al., 
2009) and cardiomyocytes (Guan et al., 2007). An alternative approach to generate 
pluripotent cells with less ethical issues is treating oocytes with activating agents, thereby 
creating haploid parthenogenetic stem cells (PSCs) (Mai et al., 2007; Revazova et al., 
2007; Sagi et al., 2016; Wang et al., 2018). Didié et al. demonstrated the ability of murine 
PSC to be differentiated into CMs just like ESCs and produced force-generating tissue, 
which was integrated into the recipient's hearts (Didié et al., 2013; Yang et al., 2015). Due 




making them easier to match to potential recipient's immune system and are therefore a 
suitable candidate for a stem cell bank for future medical applications (Wang et al., 2018). 
 
1.3.4 Induced pluripotent stem cells – a major breakthrough 
 
Finally, in 2006 Yamanaka and colleagues showed that pluripotent cells can be produced 
from normal body cells by the addition of certain factors (Takahashi and Yamanaka, 
2006). In an intensive screening approach of 24 different factors, where one factor was 
removed, and reprogramming efficiency was assessed, they identified KLF4, OCT4, 
SOX2 and C-MYC as sufficient to reprogram mouse fibroblasts to iPSCs. These cells 
were self-renewable and able to differentiate into tissue of all three germ-layers 
(Takahashi and Yamanaka, 2006). Subsequently, in 2007 Takahashi and colleagues 
demonstrated that human fibroblasts could be reprogrammed to iPSCs (Takahashi et al., 
2007). They again used OCT4, KLF4, SOX2, and C-MYC in a retroviral vector to 
reprogram the cells. The produced cells turned out to be self-renewing and were able to 
differentiate into a variety of cells and tissues, therefore being pluripotent. In sum, the cells 
behaved similarly to hESCs (Takahashi et al., 2007). Thomson and colleagues were able 
to show nearly at the same time that human iPSCs can also be produced by transduction 
of OCT3/4, SOX2, LIN28, and NANOG, thereby introducing two new reprogramming 
factors, LIN28 and SOX2 (Yu et al., 2007). These cells overcame the limitations of 
previously known cells and the discovery of their reprogramming was a major medical 
breakthrough valued with the Nobel Prize 2012.  
To eliminate the influence of remaining transgene expression or disruption of gene 
expression by transgene integration, researchers aimed for the use of non-integrating 
reprogramming methods. They used Sendai viruses (Fusaki et al., 2009), adenoviruses 
(Zhou and Freed, 2009), plasmid transfection (Okita et al., 2013), mRNA reprogramming 
(Mandal and Rossi, 2013), and even protein-based reprogramming (Kim et al., 2009; Zhou 
et al., 2009). These different reprogramming methods showed great differences in 
reprogramming efficiency dependent on the cell types used and also exhibited great 




methods such as mRNA-reprogramming (0.0-1.89% efficiency) or episomal plasmids 
(0.02-0.16%) nor integrating methods such as retroviruses (0.02%-0.06%) tested by Goh 
et al. showed consistently better performance than the other in a feeder-free 
reprogramming approach (Goh et al., 2013). After the proof of principle of iPSC generation 
from fibroblasts, a wide range of cell types was successfully reprogrammed, including 
keratinocytes (Aasen and Izpisúa Belmonte, 2010), PBMCs (Isogai et al., 2018; Loh et al., 
2009; Okita et al., 2013), and adipose-derived stem cells (Qu et al., 2012; Sugii et al., 
2011). However, it must be stated that the reprogramming efficiencies were rather low at 
the beginning (Goh et al., 2013; Takahashi et al., 2007). Huebscher et al. reported that 
the reprogramming efficiencies are dependent on the source, with PBMCs showing the 
lowest efficiency (Hübscher et al., 2019). To achieve higher rates of reprogramming, 
different substances known to interact with epigenetics have been tested and used for 
enhanced reprogramming. One example is valproic acid, an HDAC inhibitor, which 
enhanced reprogramming efficiency by a factor of 100 in experimental conditions 
(Huangfu et al., 2008). Another example is sodium butyrate, which greatly enhanced 
reprogramming in several cell types (Hubbard et al., 2014; Zhang and Wu, 2013; Zhang 
et al., 2011b). Recently, optimization efforts were very successful, as demonstrated by 
Kogut and colleagues who reprogrammed fibroblasts with mRNAs and miRNA-367/302, 
generating 4019 iPSC colonies from 500 plated fibroblasts (Kogut et al., 2018). 
Additionally, researchers try to achieve a factor-free reprogramming strategy with the help 
of small molecules. In the mouse setting, there has been substantial progress towards 
this goal by replacing all factors with small molecules (Hou et al., 2013) thereby creating 
integration free and defined iPSCs.  
 
1.3.5 The Yamanaka factors trigger a complex pluripotent network 
activation in cells 
 
The main factors in the pluripotency network factors are the genes OCT4 and SOX2 (Li 
and Belmonte, 2017; Nichols et al., 1998). OCT4 itself is regulated by SOX2 on a 
transcriptional level (Li and Belmonte, 2017; Masui et al., 2007). NANOG, while not 




expression can remain pluripotent. They are, however, unable to differentiate into germ 
cells (Chambers et al., 2007). KLF4 seems to be involved with chromatin organization and 
long-range control of factors such as OCT4 (Di Giammartino et al., 2019; Li and Belmonte, 
2017; Wei et al., 2013). MYC is important in maintaining proliferation during 
reprogramming and cells with low MYC levels are prone to cell death. Additionally, it 
silences genes associated with the somatic fate of the cell (Díaz-Díaz et al., 2017; Rand 
et al., 2018; Takahashi and Yamanaka, 2016). 
It is currently believed that reprogramming takes part in two steps (Takahashi and 
Yamanaka, 2016). During the first step, tissue-specific factors are repressed, and early 
pluripotency markers are expressed. This step is connected with a huge epigenetic barrier 
and thus can be enhanced by epigenetic modulators including HDAC inhibitors such as 
sodium butyrate (Liang et al., 2010; Takahashi and Yamanaka, 2016). In the second step, 
the late pluripotency genes are upregulated in a more controlled way than the early genes 
(Buganim et al., 2012; Takahashi and Yamanaka, 2016). To explain the low efficiency of 
reprogramming, several models, including an elite cell model where only a small portion 
of a cell population is in principle suitable for reprogramming have been proposed 
(Takahashi and Yamanaka, 2016). However, researchers now think that in principle, all 
cells can be reprogrammed and that the key lies in the induction of pluripotency. A slight 
imbalance of the different reprogramming factors, which is likely to occur, might tilt the 
fragile balance towards a different cellular fate, thereby inhibiting reprogramming efforts 
(Takahashi and Yamanaka, 2016). Wernig and colleagues demonstrated this quite 
elegant by using a doxycycline-inducible cassette with the four Yamanaka factors, which 
achieved a very balanced expression of these factors (Wernig et al., 2008). The induction 
by doxycycline caused a very high percentage of reprogramed cells (Wernig et al., 2008).  
Concerning desoxyribonucleic acid (DNA) methylation and epigenetics, it is of note that 
iPSCs keep the methylation of their parental cells for some time (Bar-Nur et al., 2011). 
Therefore, it can be problematic to differentiate these cells properly for some time. 
However, after some passages, this epigenetic memory is lost and the cells can be readily 




ease the differentiation process towards the parent-cell lineage (Bar-Nur et al., 2011; Ma 
et al., 2014; Noguchi et al., 2018). 
 
1.3.6 iPSCs can be differentiated towards a wide range of cells 
 
To fully unleash the potential of pluripotent cells, sophisticated differentiation protocols 
had to be developed. With the knowledge of human developmental signaling pathways 
and screening approaches, successful differentiation of iPSCs towards cardiomyocytes 
(Zhang et al., 2009), neurons (Chang et al., 2011; Egawa et al., 2012; Lee et al., 2009; Lu 
et al., 2012), skeletal muscles (Borchin et al., 2013), immune cells (Kennedy et al., 2012), 
hepatocytes (Liu et al., 2011; Rashid et al., 2010) and many more functional cell types 
were achieved.  
 
1.3.7 Cardiac differentiation of iPSCs 
 
To obtain optimal results during disease modeling and regeneration, it is of utmost 
importance to achieve a good differentiation and maturation of the cells. In the case of 
cardiomyocytes, the first approach was to spontaneously differentiate the cells in a 
random way and select the cardiomyocyte manually by excising beating areas (Zhang et 
al., 2009). The yield of cardiomyocytes from this method was rather poor and the method 
itself is rather time-consuming. Nevertheless, these embryoid body (EB) methods have 
been careful and systematically improved, resulting in tremendously increased yields 
(Mummery et al., 2012). That was achieved by adding extra cells in coculture to enhance 
differentiation (Mummery et al., 2003) or the addition of proteins or small molecules 
(Burridge et al., 2007; Freund et al., 2008; Kattman et al., 2011; Mummery et al., 2012).  
An alternative to EB-based methods was introduced by 2D monolayer differentiation 
methods, which are easier to handle. To achieve a better differentiation, manipulation of 
the Wnt pathway, which is also involved in human development, was performed. The Wnt-
pathway is firstly activated by CHIR99021 (CHIR) (A GSK3-inhibitor) to achieve 




the mesoderm in a cardiac-specific way (Burridge et al., 2014). Additionally, Burridge et 
al. systematically reduced the additive B27 from 27 compounds to only three essential: 
ascorbic acid, recombinant albumin, and the chemically defined medium RPMI1640 
(Burridge et al., 2014). With this method, robust differentiation is possible and relatively 
easy. To obtain an even higher purity, cardiomyocytes can be selected with a glucose-
deprived medium containing lactate, as cardiomyocytes metabolize lactate as an energy 
source (Burridge et al., 2014). Using this approach, cardiomyocytes with a high purity of 
up to 95% TNNT2-positive cells can be produced (Burridge et al., 2014).  
The differentiated pure cells, however, were still not mature, as was seen in the expression 
of ion channels and electrical behavior. This is very understandable as the human heart 
takes years to mature (Ahmed et al., 2020; Vreeker et al., 2014). To obtain more mature 
cells, different strategies were developed. Some groups used protein supplements and 
chemical molecules to enhance maturation, whereas others used special scaffolds and 
matrixes to achieve this goal. Naturally, the most obvious strategy is a longer maturation, 
which was used by Lundy et al., showing an improvement in contraction and Ca2+ handling 
after cultivation of 80–120 days versus 20–40 days (Lundy et al., 2013). Cardiomyocyte 
properties are also depending on the surface they are cultured on (Wang et al., 2011). 
Wang and co-workers showed that different nanogrooved substrates affected the 
orientation and contractile functions of cultured rat cardiomyocytes (Wang et al., 2011). 
Ruan and colleagues used mechanical stimulation to produce more mature human iPSC-
CMs (Ruan et al., 2016). Additionally, T3 was used in one study to boost maturation and 
caused stronger contraction force and improved Ca2+ handling (Yang et al., 2014). Further 
improvement was achieved by combining T3 with dexamethasone on a matrigel mattress, 
resulting in improved Ca2+ coupling and the presence of a T-tubule network in human 
iPSC-CMs (Parikh et al., 2017). Another approach is tissue culture, as demonstrated by 
Tiburcy et al. producing engineered heart muscle by combining iPSC-CMs with 
fibroblasts, thereby achieving force generation and CM form and connection comparable 
to neonatal cardiomyocytes (Tiburcy et al., 2017). Additionally to pure cardiomyocyte 
differentiation, researchers further aimed to produce certain subsets of cardiomyocytes 
such as ventricular cells, atrial cells, or pacemaker cells, since these cells are very useful 




retinoic acid, cardiomyocytes of the atrial type could be produced from ESCs (Zhang et 
al., 2011a) and iPSCs (Cyganek et al., 2018). Weng and colleagues used a combination 
of BMP4, activin-A, and IWR-1 to obtain ventricular iPSC-CMs of purities of more than 
90% (Kolanowski et al., 2017; Weng et al., 2014). Nodal cardiomyocyte production is not 
yet as effective as ventricular cardiomyocyte generation (Kolanowski et al., 2017). 
However, NRG-1β and ErbB inhibitors were used successfully in the generation of nodal-
like cells (Zhu et al., 2010). 
 
1.3.8 Disease modeling with the help of iPSCs - a step towards future 
drug screenings 
 
Disease modeling is another important use of the new iPSC-technology with its unlimited 
cell source of different tissues.  Figure 3 shows typical applications of iPSCs in this field. 
They can serve as an unlimited source of specialized cells used for disease modeling and 
subsequent drug or safety screenings. According to Avior and colleagues, for modeling 
human diseases with iPSCs, the disease of choice should fulfill some criteria: The disease 
should have high penetration, should be monogenetic, early-onset, and have a clear 
cellular phenotype (Avior et al., 2016). Consequently, complex genetic backgrounds, late 
onset of the disease and low penetration increase the difficulty of disease modeling (Avior 
et al., 2016). With the help of iPSCs-derived cells, many genetic and non-genetic diseases 
were modeled in vitro with differentiated iPSCs.  
A growing number of diseases have already been modeled with the help of iPSC-derived 
neurons, such as Alzheimer’s disease (Jones et al., 2017), Parkinson’s disease (Ren et 
al., 2015), amyotrophic lateral sclerosis (Burkhardt et al., 2013; Egawa et al., 2012; 
Sances et al., 2016) and even diseases as schizophrenia (Da Silveira Paulsen et al., 2012; 
Paulsen et al., 2014). In the cardiology field, there are several known genetic diseases, 
which have been modeled with the help of iPSC-CMs. Some examples include 
catecholaminergic polymorphic ventricular tachycardia (Kujala et al., 2012; Zhang et al., 
2013), long QT syndrome 1 (Moretti et al., 2010), 2 (Matsa et al., 2011) and 3 (Bellin et 




arrhythmogenic right ventricular cardiomyopathy (Ma et al., 2013), Brugada syndrome 
(Veerman et al., 2016), Barth syndrome (Dudek et al., 2013), anthracycline-induced 
cardiomyopathy (Burridge et al., 2016; Haupt et al., 2020), and familial dilated 
cardiomyopathy (Bellin et al., 2012; Streckfuss-Bömeke et al., 2017; Sun et al., 2012). 
 
Figure 3: Use of iPSCs in medical research. A: Use of differentiated cells as a human 
disease model. The cells recapitulate the individual phenotype of the patient. B: These 
models can then be used for drug screenings. C: The differentiated cells can also be used 
as toxicity screening models in the pharmaceutic industry to improve preclinical trial quality 
and validity. (Bellin et al., 2012). License number provided by the Copyright Clearance 
Center: 4932720740448 
Interestingly, also epigenetic diseases have been modeled. Sagie and colleagues were 
able to model immunodeficiency, centromere instability and facial anomalies syndrome, 
which is caused by a defect in a methyltransferase, causing a hypomethylation (Sagie et 
al., 2014).  
These new disease models provide valuable insights into the pathophysiology of different 
diseases. Most importantly, these models provide the possibility to develop and test new 
therapies and drugs in a human setting (Figure 3).  
 





It is no surprise that the possibility of an unlimited cell source of nearly any cell type 
triggered great hopes in the broad field of regenerative medicine. One big leap forward in 
the emerging field of regeneration was the cure of sickle cell anemia in mice by 
transplantation of bone marrow progenitor cells made from skin-derived iPSCs (Hanna et 
al., 2007). Furthermore, neuronal regeneration studies were performed in a monkey 
model of Parkinson’s disease (Kikuchi et al., 2017). One especially promising therapeutic 
approach seems to be the regeneration of pancreatic islet cells to cure diabetes, which 
was shown to reconstitute insulin production in a mice diabetic model (Yabe et al., 2019).  
Concerning cardiac regeneration, studies in larger animal models were completed lately 
by Shiba and colleagues who transplanted allogenic iPSC-derived cardiomyocytes in 
monkeys (Shiba et al., 2016). They show that the cells not only survive and couple to the 
host cardiomyocytes electrically but also that the infarcted hearts of the monkey treated 
with the produced cardiomyocytes show a better outcome than the untreated hearts. 
However, they also state that there are risks associated with their procedure in the form 
of ventricular arrhythmias, which occurred in their model (Shiba et al., 2016). Masumoto 
and co-workers used engineered cardiac tissue constructs composed of cardiomyocytes, 
endothelial cells, and vascular mural cells to ameliorate heart infarcts in rats (Masumoto 
et al., 2016). In 2012, Templin et al. demonstrated with elegant experiments using sodium 
iodide symporter labeling of cardiomyocytes injected into pigs, that cell populations can 
be traced in vivo for up to 15 weeks (Templin et al., 2012). Chong and colleagues injected 
one billion cardiomyocytes into infarcted monkey hearts and showed that the engrafted 
cells couple electrically with the host cells. The observed cells show a synchronized Ca2+ 
pattern. However, in many animals of the study, non-lethal arrhythmias were observed 
(Chong et al., 2014). Lately, more complex approaches emerge, for example, using a 
mesenchymal stem cell patch transplanted onto hearts supplemented by iPSC-CMs 
injection into rat hearts (Park et al., 2019). Menasché and colleagues used ESC-derived 
cardiac progenitors for clinical transplantation onto a human heart in a patient suffering 
from heart failure (Menasché et al., 2015). They showed that the transplanted patch was 
able to beat with the rest of the heart and no problems such as rejection or arrhythmias 
were reported in the study (Menasché et al., 2015). In a follow-up study, they were able 




an increased motion of the transplanted area was observed (Menasché et al., 2018). Jiang 
et al. injected human iPSC-CMs into infarcted hearts to ameliorate the myocyte loss, 
generating improved function (Jiang et al., 2020). Surprisingly, most of the injected cells 
were lost. However, there were some improvements, which have been thought to be 
connected to the endocrine activity of the injected cells (Jiang et al., 2020). 
In many diseases, a gene correction is necessary before a regenerative approach can be 
considered. Some groups managed to correct the causative mutations in vitro with 
genome-editing methods. A good example of that is the correction of the α1-antitrypsin 
mutation with the help of zinc-finger nucleases by Yusa et al., which showed that future 
gene therapies are possible (Yusa et al., 2011). Lately, the correction of some 
monogenetic human diseases was performed in iPSCs with the help of CRISPR/Cas9 
(Jacków et al., 2019; Yingjun et al., 2019; Yumlu et al., 2019). It was shown that gene-
corrected iPSC-based skin grafts generated from dystrophic epidermolysis bullosa 
patients showed no disease in mice (Jacków et al., 2019). Furthermore, β-thalassemia 
was corrected in iPSC cells from patients (Yingjun et al., 2019) with the result that the 
corrected and differentiated iPSCs were able to produce functional hemoglobin after 
transplantation in mice (Ou et al., 2016). Moreover, Hanses et al. demonstrated successful 
disease modeling and intronic CRISPR repair of the LZTR1 gene in an iPSC-CM system 
(Hanses et al., 2020). Additionally, Duchenne muscular dystrophy has been repaired 
using CRISPR in iPSC approaches (Li et al., 2014; Young et al., 2016). 
One hurdle with cell transplantation is the immune response. Normally, autologous iPSCs 
or their differentiated cells should not cause any immune response. However, new studies 
suggest that there can be an immune response based on NK-cells (Dressel et al., 2010). 
In a different approach, Shiba et al. demonstrated that allogenic iPSC-CMs were 
successfully transplanted in a monkey MI model, thereby improving ventricular function 
(Shiba et al., 2016). Monkeys were treated with prednisolone and tacrolimus and no 
immune rejection was observed (Shiba et al., 2016). Morizane et al. demonstrated that 
immune suppression and MHC matching ameliorated the immune response towards 
iPSC-derived, transplanted dopaminergic neurons (Morizane et al., 2017). Interestingly, 




neuronal grafts in a Huntington’s disease model in non-human primates (Badin et al., 
2019). Despite the grafts being HLA matched, a rejecting immune response was 
observed. This response, however, was more delayed than in non-matched grafts (Badin 
et al., 2019).  
 
1.3.10 Importance of differentiated iPSCs for safety screenings  
 
Nowadays, iPSC-based cells are widely used to perform safety screenings during drug 
development. This method is evermore expanding in importance as it may replace animal 
screening models to a certain extend and are closer to human physiology than the 
aforementioned animal models. Until now, several screening platforms have been 
established, like the screening of cardioactive drugs for their influence on cardiac ion 
channels and, therefore possible arrhythmias (del Álamo et al., 2016). Another example 
is the work of Sharma and colleagues, who performed a high throughput screening of 
tyrosine kinase inhibitors for cardiotoxicity (Sharma et al., 2017). Today more and more 
sophisticated disease and drug screening models are developed. For example, it has 
become quite common to use 3D structures made from cardiomyocytes and fibroblasts 
as a modeling and therapeutic platform (Tiburcy et al., 2017). These EHM can provide 
very useful insights as they represent a more complex interplay between cells and cell 
types as can be seen in 2D cultures and therefore resemble the situation in the human 
heart in a more accurate way (Huebsch et al., 2016; Tiburcy et al., 2017). Furthermore, 
commercially available platforms have been developed, which employ several cell types 
made from iPSCs on a chip to enable organ-based drug screenings as drugs often 
influence several tissues. Automated or semi-automated screening systems for ion 
channels and electrical behavior of the cells supplement these systems and open up new 
possibilities in drug screening and help to improve safety pharmacology. As in EHM, 
several cell types, which contribute towards tissues, become more and more used in the 
iPSC field in the form of organoids, thus providing more accurate drug screening 
platforms. IPSC-derived brain organoids consist of different cell types like glia and 
neurons and exhibit network activity between neurons (Zafeiriou et al., 2020). Recently, 




self-organized, consisted of atrial- and ventricular-like cells, and also contained 
endothelial cells (Lee et al., 2020). These organoids will greatly enhance drug screenings 
and disease model approaches in the future, as they can model the complex interplay of 
different cell types in organs. 
 
1.3.11 Limitations of iPSCs applications 
 
The new possibilities available by the use of iPSCs can advance the scientific and 
industrial field. However, some disadvantages exist. The production of iPSCs is costly and 
rather time-consuming, which is also true for their maintenance and differentiation. It can 
be argued that these cells do not exist in nature and will always be an artificial system. 
Dependent on the source cell type, there is also heterogeneity in stem cell gene 
expression, which can complicate the reproducibility of experiments and differentiation 
(Ghosh et al., 2010; Streckfuss-Bömeke et al., 2013). Furthermore, at the moment, most 
differentiation methods do not produce pure populations of cells (Burridge et al., 2014). It 
is unlikely that in vitro and in vivo differentiated cells will behave similarly in every situation. 
However, as mentioned earlier, differentiation and maturation protocols have been 
improved tremendously in the past. 
The used iPSC models do provide single or multiple cell types and do not yet provide the 
context of a whole organic system, as normal animal studies can provide. This might be 
problematic, as diseases often cause complex interactions between different organ 
systems. Organoids made from iPSCs have been used to mimic organic tissues (Kawada 
et al., 2017; Lancaster et al., 2013). Furthermore, in iPSC models, there is always the 
need for well-characterized adequate controls to reduce variability, which are difficult to 
obtain. Ideally, isogenic controls with a corrected disease-causing mutation would be used 





1.4 Aim of the thesis 
 
As TTS is a severe cardiovascular condition, this thesis aims to create a human iPSC-
based model of TTS in a dish. To achieve that, several TTS patients and healthy control 
persons will be recruited and somatic cells like fibroblasts and PBMCs will be isolated. 
The obtained cells will be reprogrammed to iPSCs with integration-free methods. The 
newly produced iPSCs will be characterized to ensure their pluripotent characteristics. 
Subsequently, the iPSCs will be differentiated into functional human cardiomyocytes of 
high purity and used for disease modeling. For this TTS model, several hypotheses are 
made: 
• First, TTS has at least a genetic component, thereby increasing the risk for affected 
person groups. 
• Second, TTS can be triggered by high levels of catecholamines. 
• Third, TTS can be modeled in a dish by stressing iPSC-CMs with catecholamines. 
• Fourth, the in vitro TTS model can be used to uncover pathomechanisms and to 
test new drugs. 
 
Based on these hypotheses, the following aims were explored: 
• Generation and characterization of pluripotency of TTS- and CTRL-iPSC lines 
• Differentiation of iPSCs into functional beating iPSC-CMs 
• Analysis of TTS and CTRL-iPSC-CMs upon catecholamine treatment regarding 
apoptosis, electrical activity, Ca2+ homeostasis, and lipid accumulation in 2D iPSC-
CMs culture 
• Analysis of catecholamine-sensitivity, desensitization and force of contraction in a 
3D-engineered heart muscle model 







2.1 Cells used in this study 
 
Table 1: List of somatic cells and generated cell lines. * already established lines in the lab of K. 
Streckfuß-Bömeke prior to project start  
 Cell source  
Somatic cells 
1-TTS-F  Skin fibroblasts from TTS patient 1  
2-TTS-F Skin fibroblasts from TTS patient 2  
5-TTS-F  Skin fibroblasts from TTS patient 5  
8-TTS-F Skin fibroblasts from TTS patient 8  
  
1-C-PBMC PBMC from healthy donor 1 
2-C-F Skin fibroblasts from healthy donor 2 
3-C-F Skin fibroblasts from healthy donor 3 
FB2* Skin fibroblasts from healthy donor FB2 
  
iPSCs 
1-TTS-1  iPSC-line 1 generated from fibroblasts 1-TTS-F of TTS patient 1 
1-TTS-2  iPSC-line 2 generated from fibroblasts 1-TTS-F of TTS patient 1 
2-TTS-1 iPSC-line 1 generated from fibroblasts 2-TTS-F of TTS patient 2 
2-TTS-2 iPSC-line 2 generated from fibroblasts 2-TTS-F of TTS patient 2 
5-TTS-1 iPSC-line 1 generated from fibroblasts 5-TTS-F of TTS patient 5 
5-TTS-2 iPSC-line 2 generated from fibroblasts 5-TTS-F of TTS patient 5 
8-TTS-1 iPSC-line 1 generated from fibroblasts 8-TTS-F of TTS patient 8 
8-TTS-2 iPSC-line 2 generated from fibroblasts 8-TTS-F of TTS patient 8 
1-C-1  iPSC-line 1 generated from PBMC of healthy donor 1-C-PBMC 
2-C-1  iPSC-line 1 generated from fibroblast of healthy donor 2-C-F 
3-C-1 iPSC-line 1 generated from fibroblast of healthy donor 3-C-F 








Primers for polymerase chain reaction (PCR) were designed by using the primer blast 
webpage from the National Center for Biotechnology Information. 










GAPDH 258 AGA GGC AGG GAT 
GAT GTT CT 
TCT GCT GAT 
GCC CCC ATG TT 
55 °C 34 
OCT4 218 GAC AAC AAT GAA 
AAT CTT CAG GAG A 
TTCTGGCGCCGG
TTACAGAACCA 
58 °C 36 
NANOG 164 AGT CCC AAA GGC 
AAA CAA CCC ACT TC 
ATC TGC TGG 
AGG CTG AGG 
TAT TTC TGT CTC 
64 °C 30 
LIN28 410 AGT AAG CTG CAC 
ATG GAA GG  
ATT GTG GCT 
CAA TTC TGT GC 
52 °C 38 
SOX2 437 ATG CAC CGC TAC 
GAC GTG A  
CTT TTG CAC 
CCC TCC CAT TT 
56 °C 43 
GDF3  311 TTC GCT TTC TCC 
CAG ACC AAG GTT 
TC 
TAC ATC CAG 
CAG GTT GAA 
GTG AAC AGC 
ACC 
54 °C 32 
FOXD3  353 GTG AAG CCG CCT 
TAC TCG TAC 
CCG AAG CTC 
TGC ATC ATG AG 
61 °C 38 
MYH6 (α-
MHC) 
413 GTC ATT GCT GAA 
ACC GAG AAT G  
GCA AAG TAC 
TGG ATG ACA 
CGC T 







63 °C 30 
ACTN1 291 AGG AGG AAG AAT 
GGC CTG AT 
GAT GCA GTA 
CTG GGC CTG AT 
60 °C 30 
cTNT 305 GAC AGA GCG GAA 
AAG TGG GA 
TGA AGG AGG 
CCA GGC TCT AT 




NR4A1 130 GTG TGT GGG GAC 
AAC GCT TC 
CCA CAG GGC 
AGT CCT TGT T 
60 °C 40 
CD36 176 CAG TTC TCA ATC 
TGG CTG TGG C 
AAC AGG GTA 
CGG AAC CAA 
ACT CA 
60 °C 40 
CPT1C 169 GCT TTC AGC TGG 
GCT ACT CA 
ACG ACA TGG 
CAG TCG ACA TT 




For integration-free reprogramming, plasmids from Okita et al. were used (Okita et al., 
2011): 
pCXLE-hOCT3/4-shp53-F was a gift from Shinya Yamanaka (Addgene plasmid # 
27077; http://n2t.net/addgene:27077 ; RRID:Addgene_27077) 
pCXLE-hSK was a gift from Shinya Yamanaka (Addgene plasmid # 27078; 
http://n2t.net/addgene:27078 ; RRID:Addgene_27078) 
pCXLE-hUL was a gift from Shinya Yamanaka (Addgene plasmid # 27080; 
http://n2t.net/addgene:27080 ; RRID:Addgene_27080) 
 
2.4 Primary antibodies 
 
The antibodies used for immunofluorescence (IF) and fluorescence-activated cell sorting 
(FACS) are listed in the following tables. 
Table 3: Primary antibodies – pluripotency 
Antigen Source Company Concentration 
hLIN28 Goat R&D; AF3757 1:300 
SOX2 Mouse R&D; MAB2018 1:50 
hOCT3/4 Goat R&D; AF1759 1:40 
hNANOG Goat R&D; AF1997 1:200 
TRA-1-60 Mouse Ab16288 1:200 





Table 4: Primary antibodies – germ layer 
Antigen Source Company Concentration 
α-SMA Mouse Sigma; A2547 1:3000 
β-Tubulin Mouse BioLegend 1:2000 
hAFP Rabbit Dako 1:100 
 
Table 5: Primary antibodies - cardiac 
Antigen Source Company Concentration 
α-Actinin Mouse Sigma; A7811 1:1000 




2.5 Secondary antibodies  
 
Table 6: Secondary antibodies used for IF and flow cytometry 


























donkey life Technologies; 
A21202 
























Phalloidin (Life Technologies; A34055) was used to stain F-actin and was coupled to the 
dye Alexa Fluor 555. 
 
2.6 Cell culture and media 
 
The following table shows additives used for cell culture: 
Table 7: Components for cell culture 
Component Supplier, catalog number 
0.25% Trypsin-EDTA  Thermo Fisher Scientific #25200056  
4′, 6-Diamidino-2-phenylindole 
dihydrochloride (DAPI)  
 
Sigma-Aldrich #D9542  
 
Albumin, human recombinant Sigma-Aldrich, #A02347 
B-27 Serum-free supplement (50x) Thermo Fisher Scientific, 
#17504044 
B-27 Supplement, minus insulin Thermo Fisher Scientific #A1895601 
Basic fibroblast growth factor (bFGF) PeproTech, #100-18B 
Bovine albumin fraction V solution (BSA, 
7.5%)  
Thermo Fisher Scientific #15260037  
 
Calcium chloride dihydrate (CaCl2) 
 
Roth #HN04  
 
CGP 20712A Sigma-Aldrich #C231 




Collagenase B Worthington Biochemical, #CLS-
AFB 
Collagenase IV Worthington Biochemical, #CLS-4 
Cytotune 2.0 Sendai Kit Life technologies: A16517 
Dexamethasone Sigma, D8893 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, #D2650 
DMEM (Dulbecco’s modified Eagle 
medium) 
Thermo Fisher Scientific, 
#11960044 
DMEM/F12 Thermo Fisher Scientific, 
#31331028 
DPBS (Dulbecco’s phosphate-buffered 
saline)   
Thermo Fisher Scientific, 
#14190169 
Epinephrine hydrochloride Sigma-Aldrich, # E4642-5G 
Essential 8 Medium Thermo Fisher Scientific, 
#A1517001 
Ethanol absolute Th. Geyer, #1025490 
Fetal bovine serum (FBS) Sigma-Aldrich, #F7524 
Erythropoietin Life technologies, #PHC2054 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich #E6758  
Gelatine Sigma-Aldrich, #48720 
Geltrex (Growth factor reduced) Thermo Fisher Scientific, 
#A1413302 
Glucose Sigma-Aldrich #G8270  
Hydrochloric acid (HCl) fuming 37 % Merck Millipore, #100317 
ICI 118,551 Sigma-Aldrich #I127 
IGF1 Peprotech #AF-100-11 
IL-3 Life technologies, #PHC0034 
Insulin Life technologies, #12585014 
Iscove’s modified Dulbecco’s medium with 
GlutaMax (IMDM) 





Isoproterenol hydrochloride  
Synonym: Isoprenaline hydrochloride 
Sigma-Aldrich, # I5627-5G 
Isopropanol  Merck Millipore #109634  
IWP2 Merck Millipore, #681671 
Knock Out Serum Thermo Fisher Scientific, 
#10828028 
L-Ascorbic acid 2-phosphate Sigma-Aldrich, #A8960 
L-glutamine (200 mM, 100x) Thermo Fisher Scientific, 
#25030024 
LB bouillon (Miller) Merck #1102850500 
Mitomycin C Serva Electrophoresis, #29805.02 
Monothioglycerol (MTG) Sigma-Aldrich, #M6145-25ML 
Non-essential amino acids (NEAA, 100x) Thermo Fisher Scientific, 
#11140035 
Penicillin-streptomycin solution (P/S) 
(100x) 
Thermo Fisher Scientific, 
#15140112 
Polyfect Qiagen #301105 
RPMI 1640 with HEPES with GlutaMAX Thermo Fisher Scientific, 
#724000021 
RPMI 1640 without HEPES without 
Glucose  
Thermo Fisher Scientific, 
#11879020 
Sodium DL-lactate solution 60% (w/w) Sigma-Aldrich, #L4263 
Sodium Selenite Sigma, #S5261 
Stem cell factor (SCF) Life technologies, #PHC2115 
TGF-b1 Peprotech #AF-100-21C 
Thiazovivin (TZV) Merck Millipore, #420220 
Trypsin/EDTA (0.25%) Thermo Fisher Scientific, #2520056 
VEGF165 Peprotech #AF-100-20 






Media and supplements and their preparation are stated in the following table: 
Table 8: Medias and supplements 
Name composition 
bFGF 100 µg bFGF dissolved in 1 ml Tris (5 mM) and stored at -20 °C; 





7 μl diluted in 10 ml DPBS and sterile filtered, stored at 4°C  
 
Blood medium 50% IMDM 
50% Ham’s F12-Nutrient Mix 
5 mg/mL albumin 
1x lipid concentrate 
14 ng/mL sodium selenite 
64 µg/mL L-ascorbic acid 2-phosphate 
10 µg/mL insulin, 100 µg/mL transferrin 
1 mM dexamethasone 
450 µM 1-thioglycerol 
50 ng/mL stem cell factor 
2 U/mL erythropoietin 
40 ng/mL IGF-I  
10 ng/mL IL-3 
BSA (1%) 
 





500 ml RPMI 1640 with HEPES with GlutaMAX, 10 ml B-27 






500 ml RPMI 1640 with HEPES with GlutaMAX  
250 mg albumin (human recombinant)  
100 mg L-ascorbic acid 2-phosphate 





80 ml Cardio Culture Medium 
20 ml FBS 









500 ml RPMI 1640 without HEPES without GlutaMAX 
2 ml lactate/HEPES (1 M) 
250 mg albumin (human recombinant) 
100 mg L-ascorbic acid 2-phosphate 





5 mg CHIR99021 dissolved in 0.894 ml DMSO 




dissolved in RPMI medium to a working solution of 400 U/ml 





dissolved in DMEMD/F12 to a working solution of 200 U/ml, 
sterile-filtered and stored at 4 °C 
 
Cryopreservation 
Medium (10 ml) 
 
2 ml DMSO  
8 ml Essential 8 Medium 
20 µl TZV (2 mM) 





109.8 mg were dissolved in 10 mL water and filtered sterile (50 




500 ml Essential 8 basal Medium  
10 ml Essential 8 supplement  
 
Fetal bovine serum  
 





84 ml DMEM  
15 ml FBS (heat-inactivated) 
1 ml L-glutamine  
 




 5 ml FBS (heat inactivated)  




5 g Gelatine dissolved in 5 l distilled water, autoclaved and stored 




2 mg of geltrex aliquoted and stored at -20 °C; dissolved in 12 ml 
cold DMEM/F12 before use 
 
Human Embryonic 
Stem Cell Medium 
(hESC-Medium) 
 
500 ml DMEM/F12  
90 ml KnockOut Serum  
6 ml NEAA  
6 ml β-Mercaptoethanol (100x)  
10 ng/ml bFGF (freshly added)  













79 ml IMDM  
20 ml FBS  
1 ml NEAA  





247.7 mg were dissolved in 10 mL water and filtered sterile (100 
mM stock solution) 
IWP2 (5 mM)  
 
10 mg dissolved in 4.28 ml DMSO and incubated at 37 °C for 10 






M stock solution) 
 
3 ml of 60% sodium DL-lactate solution diluted in 18 ml of 1 M 
HEPES sodium salt solution, stored at –20 °C 
 
MTG (150 mM) 
 
13 μl MTG diluted in 1 ml IMDM and sterile filtered 
freshly prepared before use 
 
TZV (2 mM) 
 




2.7 Chemicals and solutions 
 
Table 9: Chemicals and solutions 
Component Supplier, catalog number 
2-Propanol Merck Chemicals, 1096341000 
Acetic acid (glacial) Th. Geyer, #2234-25L 
Agarose, peq Gold universal Agarose Peqlab, #732-2789 
Alkaline Phosphatase staining kit Sigma-Aldrich, #86R-1KT 
β-Mercaptoethanol Sigma-Aldrich, #M3148 
Bovine serum albumin (BSA), pH 7.0 Sigma-Aldrich, #A2153 
DAPI (4’, 6-diamidino-2-phenylindole 
dihydrochloride) 
Sigma-Aldrich, #D9542 
Demecolcine (10 µl/ml) Sigma-Aldrich, #D1925 
dNTP Mix Bioline, #BIO-39029 
DEPC-treated water Ambion, #AM9915G 
Ethanol 99%, denatured  WALTER CMP GmbH, #WAL10503 
1000 
Ficoll-Paque Plus GE-Healthcare #17-1440-02 
Fluo-4/AM, cell-permeant  Thermo Fisher Scientific #F14201  
Fluoromount-G  eBioscience #00-4958-02  




GeneAmp 10X PCR Buffer II & MgCl2 Thermo Fisher Scientific #4379878 
GeneRuler 100bp DNA ladder Thermo Fisher Scientific, #0321 
Giemsa stain Sigma-Aldrich, #GS500 
Glacial acetic acid  Merck Millipore, #1.00063.1000 
Glycerol  Roth #3783  
GoTaq G2 DNA Polymerase Promega, #M7841 
Green GoTaq reaction buffer 5x Promega, #M7911 
HEPES Roth, #9105 
HEPES sodium salt solution (1 M)  Sigma-Aldrich #H3662  
Hexadimethrine bromide (Polybrene) Sigma Aldrich #107689 
Hydrochloric acid fuming 37% (HCl) Merck Millipore #100317  
Loading buffer Applichem, #A3481 
Magnesium chloride, 25 mM Thermo Fisher Scientific, 
#N8080010 
Methanol  Merck Millipore, #106009 
Microscope slide Nunc, #177380 
Microscope slide, SuperFrost Ultra Plus Menzel, #J3800AMNZ 
Midori Green Advance  Biozym, #617004 
MuLV Reverse Transcriptase (50 U/µl) Thermo Fisher Scientific, 
#N8080018 
NHDF Kit Lonza, VAPD-1001 
Nuclease-free water Thermo Fisher Scientific, #AM9932 
Oligo d(T)16 Primer Thermo Fisher Scientific, 
#N8080128  
Paraformaldehyde (PFA) Sigma-Aldrich, #158127 
PCR buffer II 10x Thermo Fisher Scientific, 
#N8080010 
Pluronic F-127  Thermo Fisher Scientific #P3000MP  




QIAquick Gel Extraction kit Qiagen, #28706 
RNase Inhibitor Thermo Fisher Scientific, 
#N8080199 
Sodium chloride (NaCl) Roth, #9265.1 
SV Total RNA isolation kit Promega, #Z3100 
SYBR Green PCR master mix Thermo Fisher Scientific, #4309155 
Tris Roth, #5429 
Tris buffer pure Roth, #1022840 
Triton X-100 Sigma-Aldrich, #3051.3 
TrypLE Express Enzyme (1X), no phenol 
red 
Thermo Fisher Scientific, 
#12604013 
Tween 20 Bio-Rad, #170-6531 
VECTASHIELD Antifade Mounting 
Medium 
Vector Laboratories, #H-1000 
 
2.8 Devices and machines 
 
Table 10: Devices and machines 
Device Company 
  7900 HT qPCR system Thermo Fisher Scientific 
Balances: Extend 
ED153-CW, CPA225D  
 
Sartorius 









system: ChemiDoc MP Imaging 







Confocal laser scanning microscope: 















Flow cytometer: FACS Canto II   
 
BD Biosciences 
Freezing box: Mr. Frosty   
 
Thermo Fisher Scientific 
Gel documentation: MultiImage 
Light Cabinet  
 
 
Alpha Innotech Corporation 
Incubator: Labotect C200  
 
Labotect 







Microscopes: Axio Observer A1, Axio 




  Multi-Electrode Array MEA 2100 Multichannel Systems 
  Multi-Image Light Cabinet Alpha Innotech corporation 




Thermo Fisher Scientific 
PCR cycler: Thermocycler 48   
 
SensoQuest 
pH meter: inoLab pH 7110   
 
WTW 
Pipet controller: Accu-jet pro   
 
Brand 
Pipettes: Reference, Research plus 




Power supply: Power 




qPCR cycler: iCycler Thermal Cycler, 












system: Benchtop Tissue 




Water preparation system  





2.9 Disposable items 
 
Table 11: Disposable items 
Item Manufacturer 
10-cm dish, TC-treated CytoOne Starlab #CC7682-3394 
12-well plate, TC-treated  CytoOne Starlab #CC7682-7512  
6-cm dish, TC-treated  CytoOne Starlab #CC7682-3359 
6-cm dish, untreated  Sarstedt #82.1194.500 
6-well plate, TC- treated  CytoOne Starlab #CC7682-7506  
96 -well microplate, black Berthold Technologies #23302 
96 -well microplate, black, clear bottom Berthold Technologies #38840 
Cell scraper: 2-Posit. Blade 25  Sarstedt #83.1830  
Cryo tubes Thermo Fisher Scientific, #377224 
Filter tips: 0.1–1000 μL Starlab #S1120-3810, #S1122-1830, 
#S1120-1840  
Flow cytometry tube: 5 mL Polystyrene 
Round-Bottom Tubes  
BD Falcon #352058  
Pasteur pipettes Brand, #747715 
Pipette tips: 0.1–1000 μL Starlab #S1111-3700, #S1111-1706, 
#S1112-1720  





Slides and coverslips: 76 x 26 mm, 18 x 
18 mm, round 25 mm  
Thermo Fisher Scientific #10143562CE, 
Thermo Fisher Scientific #4004672; R. 
Langenbrinck, #1049251  
Sterile filters: Millex-GS, 0.22 μm; Steriflip 
50 mL, 0.22 μm; Steritops 500 mL, 0.22 
μm  
Merck Millipore #GLGS0250S  
Merck Millipore #SCGP00525  




Table 12: Software 
Software Company/Developer 
Adobe Illustrator 2020 Adobe 
Adobe Photoshop Adobe 
Adobe Reader Adobe 
ApE A plasmid editor M. Wayne Davis 
Axio Vision Carl Zeiss 
Cardio 2D Multichannel Systems 
Excel Microsoft Corporation 
Flowing Software Perttu Terho 
Graph Pad GraphPad Software, Inc 
ImageJ / Fiji Wayne Rasband, Curtis Rueden, and 
community 
Inkscape Open-Source 
IQ optical systems software Bio-Rad 
LabChart AD Instruments 
MC_Rack Multichannel Systems 
Multi Elec (Georgiadis et al., 2015) 
SparkMaster (Picht et al., 2007) 




Word Microsoft Corporation 








3.1 Cell culture techniques 
 
3.1.1 Fibroblast isolation from skin punch biopsies 
 
Fibroblasts can be isolated from different tissues. One of the most accessible tissues is 
the skin, as fibroblasts can be readily cultivated from this tissue. Skin punch biopsies were 
obtained from probands and dissected mechanically with a scalpel and placed on 6 cm 
dishes in HFBM with an additional 10 ng/ml bFGF and 2xP/S. Fibroblasts were allowed to 
grow out of the biopsy for three weeks in HFBM medium, which was changed every other 
day. For passaging, cells were incubated in 0.25 % Trypsin/EDTA until they started to 
detach. Trypsin/EDTA was removed and cells were rinsed and collected with HFBM and 
transferred to a new dish. Consequently, fibroblasts were cultivated in HFBM and used 
for iPSC-production at passages 2–7. 
 
3.1.2 PBMC isolation 
 
Human PBMCs were isolated from donor blood samples. Fifteen ml of blood were drawn 
in an EDTA-vacutainer and PBMCs were isolated. The blood was transferred to a 50 ml 
falcon tube and 35 ml DMEM/F12 was added. Two times 25 ml of the solution was added 
to two 50 ml falcons containing 20 ml Ficoll-Paque. Falcons were centrifuged at 400 g for 
40 min at room temperature without deceleration break. hPBMCs were collected from the 
interphase in a 50 mL falcon tube and DMEM/F12 was added until 50 mL total volume 
was reached. Cells were centrifuged at 750 g for 10 min at room temperature and 
supernatant was discarded. Cells were resuspended in 40 ml DMEM/F12 and centrifuged 
at 750 g for 10 min at room temperature and supernatant was discarded. Cells were 
resuspended in 1–2 ml blood medium and counted. In total, 2x106 cells were added in 
one well of a 24-well plate in blood medium with 1xP/S. Medium was changed every other 




Supernatant was discarded and cells resuspended in new blood medium and added to 
the old well. 
 
3.1.3 IPSC reprogramming of fibroblasts and PBMCS 
 
Fibroblasts were reprogrammed at passages 2–7 and PBMCs after 5–20 days post 
isolation. For reprogramming, a plasmid-based non-integrating approach was used for 
fibroblasts and a Sendai virus-based non-integrative approach was used for fibroblast and 
PBMCs.  
 
3.1.4 Plasmid reprogramming 
 
For rapid and cheap reprogramming the use of plasmids is useful as demonstrated by 
Okita et al. (Okita et al., 2011). Fibroblasts were washed once with PBS and digested with 
0.25 % Trypsin/EDTA or TrypLE for 1-2 min at 37 °C to obtain single cells. Cells were 
collected in fibroblast medium and counted. 5x105-1x106 cells were transferred to an 
Eppendorf cup and centrifuged for 10 min at 200 g. Nucleofector solution (82 µl) and 
supplement (18 µl) were mixed and the cells were resuspended in the mix. 1-2 µg of each 
of the plasmids was added and the solution was mixed properly. Cells were transferred to 
the supplied cuvettes and nucleofection was carried out in the Amaxa nucleofector II with 
program P22 or U23. Cells were carefully resuspended in HFBM and transferred to a 
prepared plate with HFBM with 2xP/S and 2 µM TZV. The cells were allowed to grow for 
one week with medium change with HFBM supplemented with 0.5 mM sodium butyrate 
every other day. Afterwards, cells were split with 0.25 % Trypsin/EDTA or TrypLE and 
diluted onto new geltrex coated 6-well plates. From day 8 on, cells were supplemented 
with essential 8 (E8) medium. From day 8 to day 11, E8 medium was supplemented with 
0.5 mM sodium butyrate to enhance reprogramming. After 30 days iPSC colonies were 





3.1.5 Sendai reprogramming 
 
Sendai viruses are integration-free RNA viruses and therefore especially useful for iPSC 
production. For reprograming, the cyto tune 2.0 Sendai virus kit from life technologies was 
used. In brief, 3x105-5x105 fibroblasts or PBMCs were used for transduction. Medium was 
removed and Sendai viruses were added to the cells in fresh HFBM or blood medium with 
1xP/S at a MOI of 2.5/2.5/1.5, 5/5/3, or 10/10/5 for the Sendai viruses hKOS, hc-Myc, or 
h-Klf4, respectively. Virus solution volumes were calculated from the virus concentration 
stated on the analysis certificate and the desired MOI (multiplicity of infection). The cells 
were incubated with the virus for 24 h and supplemented with fresh HFBM/blood medium. 
After seven days, the fibroblasts and PBMCs were transferred to a geltrex well of a 6-well 
plate, which was coated with geltrex, at a 1:2-1:24 rate and medium was changed to E8 
medium. Four to five weeks after transduction, emerging colonies were manually picked 
onto geltrex-coated 12-well plates in E8 medium. 
 
3.1.6 Cultivation of iPSCs 
 
During this work, iPSCs were either cultured on mouse embryonic fibroblasts (MEF) or 
feeder-free cultivation methods with geltrex were used. For geltrex coating, 2 mg of -20 
°C cold geltrex was dissolved in 12 ml of DMEM/F12. Twelve-well plates were coated with 
0.5 mL geltrex solution and 6-well plates with 1 ml per well. 
For feeder-free culture, IPSCs were cultivated on geltrex-coated 6-well plates and 
supplemented with E8 medium. Medium was changed every day. The cells were split 
twice per week. In brief, cells were washed with versene followed by 4 min of incubation 
with versene at room temperature. Afterwards, versene was discarded and the cells were 
collected in E8 medium supplemented with 2 µM TZV and a fraction (1:1-1:30) of them 
was transferred to new geltrex coated 6-well plates. Medium was changed to normal E8 
the next day. 
For culture on MEFs, iPSCs were incubated in hESC-medium and medium was changed 




incubation with collagenase IV (200 U/ml) for 5 min at 37 °C. Cells were washed two times 
with DMEM/F12 and a cell scraper was used to detach them. Cells were resuspended in 
hESC-medium using a 1 ml pipette and transferred to new 6 cm plates with MEF. 
 
3.1.7 Freezing and thawing of hiPSCs 
 
For feeder-free culture, one confluent well of a 6-well plate with hiPSCs was detached as 
described earlier (3.1.6) in 1 ml E8 medium and collected in a cryovial. Subsequently, 1 
ml double concentrated freezing medium was added dropwise. The cryovial was 
transferred to a -80 °C freezer in a Mister Frosty box to guarantee a slow temperature 
decrease. Frozen cells were transferred to long-term liquid nitrogen storage on the next 
day.  
IPSCs cultivated on MEFs were detached as described before. Cells were resuspended 
in DMEM/F12. The cells were centrifuged for 3 min at 200 g. DMEM/F12 was discarded 
and the pellet was resuspended in freezing medium. The cells were transferred to 
cryovials and frozen in a Mister Frosty box at -80°C. The next day, they were transferred 
to liquid nitrogen storage. 
To thaw iPSCs, cryovials were removed from liquid nitrogen storage warmed briefly in a 
37 °C water bath. Afterwards, the cell suspension was transferred to a 15 ml falcon tube 
and subsequently 10 ml of DMEM/F12 was added. Cells were centrifuged for 3 min at 200 
g, supernatant was removed and the cells resuspended in hES-Medium or E8-medium 
(with 2µM TZV) and seeded onto 6 cm dishes (feeder layer culture) or geltrex coated 6-
well plates (feeder-free culture). 
 
3.1.8 Embryoid body differentiation 
 
To test the in vitro differentiation potential of iPSCs, untargeted random differentiation via 
EBs was used. At day 0, iPSCs cultivated on MEFs were collected for comparison: 




collected in PBS with a cell scraper and centrifuged at 17,000 g for 1 min and the 
supernatant was discarded. Pellets were snap-frozen in liquid nitrogen and stored at -
80°C until usage. For EB differentiation, iPSCs cultivated on MEFs were washed with 
DMEM/F12. The cells were digested with collagenase IV for up to 5 min and washed again 
with DMEM/F12. The culture was sliced in medium chunks with the help of a cell scraper, 
collected and transferred to an uncoated 6 cm dish. After one day, the medium was 
changed to Iscove medium by collecting cells in a 15 ml falcon tube and carefully 
aspirating the supernatant followed by resuspension in Iscove medium. For the first seven 
days, the cells were cultivated in suspension culture and the medium was changed every 
other day. On day 8, a part of the culture was collected in form of a pellet by washing the 
EBs once with PBS and centrifugation of the EBs at 17,000 g for 1 min. The supernatant 
was discarded and cell pellets were snap-frozen in liquid nitrogen and stored at -80°C until 
usage. The rest of the EBs was transferred to a 0.1 % gelatin-coated tissue culture treated 
6 cm dish. Iscove medium was changed every other day. On day 8+5, one dish of EBs 
was fixed for immunostaining as described in chapter 3.2.12. On day 8+25, pellets were 
collected and the rest of the EB dishes were fixed for immunostaining as described in 
chapter 3.2.12. The pellets were used for RNA isolation and reverse transcription PCR 
(RT-PCR) and PCR for differentiation-related genes. The fixed bodies were used for 
immunostaining for β-tubulin, α-smooth muscle actin (α-SMA), and alpha-fetoprotein 
(AFP). 
 
3.1.9 In vivo differentiation of iPSCs in SCID mice 
 
One traditional method to check the pluripotency of a cell is a teratoma assay. In that 
assay, cells are injected in immunosuppressed mice, as they proliferate, subsequently 
form tissue of all three germ layers. The experiments were performed in cooperation with 
Prof. Ralf Dressel (Department of Immunology, UMG) and hematoxylin-eosin staining was 
performed by the Department of Pathology (UMG). 
Briefly, two to four 6 cm dishes of iPSCs on MEF were washed with DMEM/F12 followed 




and scraped with a cell scraper and collected in 2 ml DMEM/F12. Cells from 3x6 cm plates 
were pooled and centrifuged at 200 g for 2 min and the supernatant was discarded. Cells 
were resuspended in 200 µl DMEM/F12 before being injected into SCID mice. After 
several months and detection of palpable teratomas, mice were sacrificed and teratomas 
were explanted. Teratomas were fixed in 37 % formalin, cut into thin slices, and stained 
with hematoxylin and eosin. Stained teratomas were assessed for the occurrence of 
tissues of different germ layers by light microscopy. 
 
3.1.10 Directed in vitro iPSC-differentiation, cardiomyocyte culturing, 
metabolic selection and digestion 
 
IPSCs cultured feeder-free on geltrex were used for cardiac differentiation. Cardiac 
differentiation of iPSCs was performed by sequential manipulation of the WNT pathway 
and is depicted schematically in Figure 4. At 85–95% cell confluence, media was changed 
to cardio differentiation medium supplemented with 4 µM of the glycogen synthase kinase 
3 (GSK3) inhibitor CHIR. After 48 h, medium was changed to fresh cardio differentiation 
medium with addition of 5 µM of the inhibitor of IWP2 for two days. On day 4, medium was 
changed to plain cardio differentiation medium. From day 10 on, the cells were cultured 
in cardio culture medium. Medium was changed every two to three days. To purify iPSC-
CMs after 20–40 days of differentiation, metabolic selection was carried out by culturing 
the cells for 2–4 days in cardio-selection medium containing lactate as carbon source. 
Differentiated iPSC-CMs were studied on day 60+ after initiation of differentiation. 
Following differentiation, purity of iPSC-CMs was determined with the help of flow 
cytometry analysis. For experiments, only iPSC-CMs with purities of above 75% cTnT 
positive cells were used. 
For immunofluorescence and MEA experiments, iPSC-CMs have to be digested and 
transferred to the respective experimental surface. Cells were incubated in 0.25% 
Trypsin/EDTA at 37 °C for 5 min. Cells were detached and collected with cardio digest 
medium and transferred to a 15 ml falcon tube. After centrifugation for 5 min at 200 g, 




Subsequently, cells were transferred to geltrex coated MEAs or coverslips (for IF). After 
1-day, medium was changed to cardio culture medium. 
 
Figure 4: Schematic view of the differentiation protocol used in this study. Cardiac induction was 
performed by CHIR and IWP2 addition followed by 16 days of differentiation. Metabolic selection 
was performed using lactate. Afterwards, cells were allowed to mature until day 60. 
 
3.1.11 Iso/Epi treatment 
 
Cardiomyocytes were stressed by the addition of the catecholamines Iso and Epi to 
achieve a TTS-like phenotype. 247.7 mg of Iso were dissolved in 10 ml water and filtered 
sterile to obtain 100 mM stock solution. 109.8 mg of Epi were dissolved in 10 ml water 
and filtered sterile to obtain a 50 mM stock solution. Iso and Epi stock solutions were pre-
diluted in sterile water at 100x the desired concentrations and stored at -20 °C. For 
experiments, 1:100 dilution from the 100x stock was added to the cells to achieve 
catecholamine concentrations of 100 nM (Epi/Iso), 1 µM (Epi/Iso), 10 µM(Epi/Iso), 100 µM 
(Epi/Iso), 500 µM (Epi only), 1 mM (Iso only), 5 mM (Iso only). The cardiomyocytes were 
incubated with the catecholamines for 2 h if not stated otherwise. 
 
3.1.12 Pellet collection 
 
IPSC and iPSC-CM pellets had to be collected fast and reliable in order to analyze their 
RNA and protein content. Medium was discarded and cells were washed once with PBS. 
Subsequently, cells were collected in PBS with a cell scraper and centrifuged at 17,000 g 
for 1 min. The supernatant was discarded and pellets were snap-frozen in liquid nitrogen 





3.2 Molecular biology 
 
3.2.1 RNA isolation 
 
To analyze expression of genes, the RNA was analyzed. To isolate RNA, the SV total 
RNA isolation kit from Promega was used. The cell pellets were resuspended in 400 µl of 
lysis buffer, transferred to a new Eppendorf cup and mixed with 400 µl of 95 % ethanol. 
Solution was transferred to a spin column and centrifuged for 1 min at 13,000 g. The 
column was washed with 600 µl RNA wash solution. The column was centrifuged at 
13,000 g for 1 min. DNAse solution was added to the column and incubated for 15 minutes 
at room temperature. To stop the reaction, DNase stop solution (200 µl) was added and 
the column was centrifuged at 13,000 g for 1 min. 600 µl RNA wash solution was added 
and the column was centrifuged at 13,000 g for 1 min. 250 µl of RNA wash solution were 
added to the column and the column was centrifuged for 2 min at 13,000 g and one 
additional time at 13,000 g for 1 min. RNA elution was carried out by adding 100 µl of 
nuclease-free water to the column followed by a 1 min centrifugation at 13,000 g. RNA 
concentration was measured at 260/280 nm with a spectrometer or with a Nanodrop. 
 
3.2.2 Reverse transcription PCR 
 
To transcribe the isolated RNA into complementary DNA (cDNA) reverse transcription 
PCR (RT-PCR) was used with the help of reverse transcriptase. 
The following reaction was prepared: 
Table 13: Components for RT-PCR 
RNA 100 ng 
10x PCR buffer II 2 μl 
25 mM MgCl2 4 μl 
100 mM dNTPs 0.8 μl 




50 μM Oligo (dt)16 1 μl 
MuLV Reverse Transcriptase (50 U/μL) 1 μl 
Nuclease free water x μl 
final volume 20 μl 
 
The reaction was incubated as follows: 
Table 14: Temperature for RT-PCR 
Temperature time 
22 °C 10 min 
42 °C 50 min 
95 °C 10 min 
4 °C ∞ 
 
3.2.3 Polymerase chain reaction (PCR) 
 
To analyze expression levels of cDNA it is necessary to amplify it. This is done by PCR. 
One to two µl of cDNA reaction were added as PCR template to the reagents from Table 
15. When using two µl of cDNA nuclease-free water volume from Table 15 was reduced 
to 14.05 µl. The PCR was run for 25–35 cycles according to temperatures and incubation 
times from Table 16. 
 
Table 15: Components for PCR 
Components for PCR Volume (µl) 
cDNA 1 
Nuclease free water 15.05 
5x Green GoTaq reaction buffer 5 
10 mM dNTPs 1.6 
Forward primer (10 µM) 1 




GoTaq DNA polymerase 0.1 
DMSO 0.25  
Overall volume 25 
 
 
Table 16: Conditions for PCR 
Temperature Duration Cycle number 
95 °C 120 s 1x 
95 °C 15 s  
nx 51-66 °C 10 s 
72 °C 20 s 
95 °C 15 s 1x 
60 °C 10 s 72x 
4 °C ∞  
 
GAPDH was used as control. Table 2 contains primer sequences, cycle number (n)  and 
annealing temperatures used for PCR analyses. For visualization, 1–2% agarose gels 
with 6 µl Midori green was used. Gels were loaded with 15 µl PCR products (already 
containing loading buffer from the 5x Green GoTaq reaction buffer) and run at 100 V for 
30–45 min. 7 µl of the Gene Ruler 100 bp DNA ladder was used for size comparison. 
Visualization and image acquisition were carried out in a MultiImage Light Cabinet. 
 
3.2.4 Quantitative PCR 
 
Quantitative PCR (qPCR) was used to quantify gene expression on mRNA level. For this 
purpose, fluorescent SYBR green was used to quantify cDNA in the setting of a PCR. To 
perform qPCR, the following amounts were used in a 96-well or 384-well format: 





10 µl SYBR Green 
 
5 µl Sybr Green 
7 µl nuclease-free water 
 
3.5 µl nuclease-free water 
1 µl primer forward 
 
0.25 µl primer forward 
1 µl primer reverse 
 
0.25 µl primer reverse 
1 µl cDNA sample 1 µl cDNA sample 
 
The following temperature settings were used for 96-well plates in a BioRad qPCR 
system. 
Table 18: Temperature, duration, and cycle setup for the BioRad qPCR system 
Temperature Duration Cycle number 
95 °C 120 s 1x 
95 °C 15 s  
40x 60 °C 10 s 
72 °C 20 s 
95 °C 15 s 1x 
60 °C 10 s 72x 
4 °C ∞  
 
Temperature settings in 384-well plates in the 7900 HT system were as follows. 
Table 19: Temperature, duration, and cycle setup for the 7900 HT qPCR system 
Temperature Duration Cycle number 
50 °C 120 s 1x 
95 °C 600 s 1x 
95 °C 15 s 40x 
60 °C 60 s 




60 °C 15 s 72x 
95 °C 15 s 1x 
 
GAPDH was used as a control and the qPCR was analyzed and normalized to it via the 
delta Ct method. In brief, Ct values of GAPDH were subtracted from the Ct values of the 
gene of interest of the same sample. 
 
3.2.5 DNA isolation and sequencing 
 
For genetic analysis, isolation of genomic DNA was necessary. The Maxwell 16 DNA 
purification kit (Promega) was used in combination with the automatic Maxwell 16 
instrument. Cell pellets were resuspended in 350 µl PBS and placed in a provided 
cartridge. Three-hundred µl of the elution buffer were added to the elution tube. A plunger 
was loaded into its respective well, the cartridge was placed in the Maxwell 16 instrument 
and the program “Cells” was carried out. Afterwards, the remaining magnetic beats were 
removed with the help of a magnetic rack. The eluate was collected and DNA 
concentrations were measured at 260/280 nm in a photo spectrometer. 
One-hundred ng of the isolated DNA were used as PCR template and the region of 
interest was amplified by PCR as described in chapter 3.2.3. The product was run on a 
1.5% agarose gel as described in chapter 3.2.3 and the desired DNA fragment was cut 
out with a scalpel. The product was purified with QIAquick Gel Extraction Kit (Qiagen). 
The gel fragment was weighted to estimate the volume of the fragment. One volume of 
gel fragment was mixed with 3 volumes of QG buffer and one volume of isopropanol. The 
solution was transferred to a QIAquick column and centrifuged at 13,000 g for 1 min. The 
flow-through was discarded. Afterwards, the column was washed by addition of 750 µl of 
PE buffer followed by another 1 min centrifugation step at 13,000 g. The flowthrough was 
discarded and the centrifugation was repeated. The column was placed in a 1.5 ml 
eppendorf cup and the DNA was eluted by adding 50 µl of nuclease-free water and 
centrifugation was carried out at 13,000 g for 1 min. DNA concentrations were measured 




sequencing primer and 67.5 ng DNA were mixed in 15 µl nuclease-free water. The 
sequencing itself was done externally by Seqlab Sequencing Laboratories GmbH. Results 
were analyzed with ApE. 
 
3.2.6 Alkaline phosphatase (ALP) staining 
 
Pluripotent stem cells express ALP. The enzyme can be visualized by using its catalytic 
activity. To stain for ALP, a staining kit (Sigma-Aldrich, #86R-1KT) was used. Fixation 
solution was prepared as follows: 13 ml acetone, 5 ml citrate solution, and 1.6 ml 37% 
formaldehyde were mixed in a glass bottle. Cells were washed two times with PBS. 
Fixation solution was added and dishes were incubated for 30 seconds. Cells were 
washed twice with water. Staining solution was prepared as follows: 0.5 ml FRV-alkaline 
solution was mixed with 0.5 ml sodium nitrate and incubated for 2 min at room 
temperature. Then, 22.5 ml water and 0.5 ml Naphthol AS-B were added. The staining 
solution was added and incubated for at least 15 min at 37 °C in the dark. The cells were 
washed two times with water and air-dried overnight. 
 
3.2.7 Annexin V/PI staining 
 
Apoptosis is the process of regulated cell death and often occurs under intensive stress 
conditions. To quantify the rate of apoptosis in our system, a combination of annexin V 
and propidium iodide (PI) staining was used. It is a hallmark of annexin V that it is normally 
located in the inner cell membrane. Only if apoptosis starts, the cell membrane starts to 
lose its normal organization and annexin V can be stained with extracellular staining at 
the outer cell membrane. PI is a DNA staining agent and stains late apoptotic or necrotic 
cells, with DNA being abundant all over the cell due to membrane damage.  
The cells were digested with 0.25% Trypsin/EDTA, collected in FBS, and counted. After 
a centrifugation step at 200 g for 3 min, 1x106 cells/ml were resuspended in PBS. Cells 
were centrifuged at 200 g for 3 min and subsequently resuspended in 500 µl annexin V 





5 µl Annexin V 
10 µl PI solution 
5 µl annexin V and 10 µl PI solution 
The stainings were incubated at room temperature for 15 min in the dark. 400 µl annexin 
v binding buffer was added and 10,000 cells were analyzed with a flow cytometer and 
recorded with the FACSDiva software. Analysis for the fraction of annexin v positive and 
annexin v/PI (necrotic) positive cells was performed with flowing software. 
 
3.2.8 Analysis of sarcomeric regularity 
 
To analyze sarcomeric regularity, iPSC-CMs were stained for α-actinin, as described 
previously. FIJI with the integrated plugin “Tubeness” was used on the obtained images. 
Next, the fast Fourier transform algorithm was used on the data. The resulting frequency 
domains were radially integrated with the help of the open-source plugin “Radial Profile 
Plot” from Paul Baggethun. Finally, analysis of the relative amplitude of the first peak of 
the intensity profile was performed with LabChart. This extracted amplitude level was used 
to analyze the regularity of sarcomeres in the iPSC-CMs. 
 
3.2.9 cTnT flow cytometry analysis 
 
To quantify the efficiency of the cardiac differentiation, flow cytometry for the cardiac 
marker cTNT was performed. Briefly, cardiomyocytes were digested for 10 min with 0.25% 
Trypsin/EDTA to obtain single cells. Digestion was stopped with cardio culture medium 
with 20% FBS and cells were counted. 250,000 cells per tube were collected and 
centrifuged for 5 min at 200 g. Cells were washed once with PBS. Fixation was performed 
in 4% PFA for 20 min at room temperature. After fixation, cells were washed twice with 




in PBS. Cells were incubated with the primary antibody (cTNT 1:500 in 0.1% Triton-X 
100/1 % BSA) overnight at 4 °C. Cells were washed two times with Triton-X 100/1% BSA 
in PBS and the second antibody (Alexa 488) was added in 0.1 % Triton-X 100/1% BSA. 
The secondary antibody was incubated for 45 min at 37 °C in the dark. Cells were washed 
two times with 0.2% BSA. Cells were resuspended in PBS and 10,000 cells were analyzed 
using a flow cytometer with the FACS Diva software. Unstained cells were used as 
negative control and cells stained only with the secondary antibody were used to perform 
gating settings. Analysis was performed with the FACS Diva software and flowing 
software. 
 
3.2.10 Ca2+ imaging 
 
Cardiomyocyte contraction relies on cyclic Ca2+ changes in the cells, which are 
characterized by Ca2+ transients and Ca2+ sparks. For Ca2+ imaging iPSC-CMs were 
cultivated on round coverslips coated with geltrex. To visualize these Ca2+ fluctuations, 
fluo-4 based Ca2+ imaging is used. 
Cells were imaged in Tyrode solution: 
NaCl  140 mM 
KCl  5.4 mM 
MgCl2  1 mM 
HEPES 10 mM 
Glucose 10 mM 
CaCl2  1.8 mM 
50 µg Fluo4 were solved in 44 µl DMSO to obtain a stock solution. Two µl of the stock 
solution were mixed with 0.5 µl pluronic and mixed with 400 µl Tyrode to obtain a staining 
solution. Coverslips with iPSC-CMs were attached to the Ca2+ measuring chamber and 




nM), or both. After staining, cells were washed twice with Tyrode and measured in Tyrode. 
After measuring basal conditions, fresh Tyrode with increasing Iso concentrations and 
CGP/ICI depending on the conditions was added.  
Cells were measured with a Carl Zeiss LSM 710 confocal microscope and a 63x 1.4 NA 
oil objective in line scan mode (512 pixels, 45.5 µm, 1057.7 Hz, 20,000 cycles). For Fluo-
4 excitation was done at 488 nm and emission was detected at 490–540 nm. The pinhole 
was set to 6 airy units. 
The analysis was performed with GraphPad, Excel, Fiji, and LabChart. For Line scan 
intensity export, Fiji was used. Exported data were smoothed with GraphPad and 
consequently analyzed with LabChart. T50 was defined as the time from peak fluorescence 
until 50% signal decay. The rise time was defined as the time from transient start to the 
time of maximum level of the transient. 
 
3.2.11 Ca2+ spark analysis 
 
Cardiomyocytes typically show Ca2+ sparks, which are small spatially defined Ca2+ leaks. 
Excessive Ca2+ leakage through sparks can be disease-causing, therefore Ca2+ sparks 
were analyzed. For analysis, line scans of iPSC-CMs were recorded as described earlier. 
In each line scan, a rectangle shape area with a width of 40 µm and a length of one second 
was analyzed with the Fiji plugin SparkMaster. The rectangle was positioned just before 
the start of a Ca2+ wave to obtain diastolic data. The threshold to identify sparks was set 
to 3.5 and the picture was split into 3 intervals by SparkMaster. Spark data were collected 
and ordered with excel and additional criteria to exclude small sparks were added. The 
used criteria were as follows: 
- a minimum full width at half maximum (FWHM) of 1 µm 
- a minimum full duration at half maximum (FDHM) of 8 ms 




The spark numbers per cardiomyocyte, the mean FWHM, the mean FDHM, and total Ca2+ 
leak (sum of (FWHM*FDHM*Amplitude) of all sparks in a single iPSC-CM) were included 
in the analysis. 
 
3.2.12 Immunofluorescence staining 
 
To visualize expressed proteins in a cellular context, immunofluorescence with target-
specific antibodies and fluorescence tagged secondary antibodies were used. Cells were 
washed 3 times briefly with PBS. Afterwards, cells were fixed with 4% PFA solution for 20 
min. PFA was discarded and cells were washed 3 more times with PBS. Cells were stored 
in 1 % BSA solution until staining was performed. Cells were stained with the primary 
antibody diluted in 0.1% Triton-X 100/1% BSA in PBS and. Staining was performed 
overnight at 4 °C. The next day, staining solution was discarded and cells were washed 3 
times with PBS. Secondary antibodies were diluted in Triton-X 100/1% BSA in PBS, added 
to the cells, and incubated in a moist chamber at 37 °C for 1 hour. Subsequently, staining 
solution was discarded and cells were washed with PBS. For nuclear staining, cells were 
incubated with a 1:5000 DAPI solution in water for 10 min at room temperature in the dark. 
Cells were rinsed with PBS and water. The stained cells were mounted with fluoromount-
G on a coverslip. Images were acquired using a fluorescence microscope (Axiovert 200, 
Zeiss).  
 
3.2.13 Oil Red O staining 
 
To visualize lipid droplets in cells, a fatty acid stain with Oil Red O is easy and efficient. 
The cells were incubated with Iso/Epi for 2 h and washed three times with PBS. 
Afterwards, cells were fixed with 4% PFA for 20 min and washed three times with PBS. 
Cells were preincubated in 60% isopropanol for 5 min and 0.3% Oil Red O solution (in 
60% isopropanol) was added. After incubation for 20 min, cells were rinsed with tap water 
and stained with Mayers Hämatoxilin for 1 min and rinsed again with tap water. 









For karyotyping, cells were incubated with Demecolcemid 100 ng/ml for 12–16 h. The 
supernatant was collected and cells were rinsed with PBS. Cells were digested with 
TrypLE for 45 s, harvested, and pooled. Cells were centrifuged at 200 g for 5 min. 
Afterwards, most of the supernatant was discarded and cells were carefully resuspended 
in the remaining supernatant. 6–8 ml pre-warmed 37 °C 0.075 M KCl solution was added 
dropwise up to 8 ml to the cells while constantly shaking the tube. The cells were incubated 
at 37 °C for 45 min. The solution was centrifuged for 5 min at 200 g, most of the 
supernatant was discarded and the cells were resuspended in the remaining 500 µl 
supernatant. Cooled methanol-acetone solution (3:1) was added dropwise under constant 
shaking up to 5 ml and the solution was incubated on ice for 10 min. The solution was 
centrifuged for 3 minutes at 200 g. This fixation step was repeated two more times. After 
fixation, cells were resuspended in 2 ml methanol-acetone solution and dropped from 50 
cm height on prepared microscope slides. The cell spreads were allowed to dry overnight. 
Chromosomes were stained in giemsa solution (1:20 in water) for 5 min at RT. Cells were 
rinsed several times with water and allowed to dry. Images were acquired by the Zeiss 
Axio Imager M2 light microscope. Karyotypes were analyzed with the Case Data Manager 
6.0 software (Applied Spectral Imaging, ASI). 
 
3.2.15 Multi-electrode arrays 
 
IPSC-CMs were analyzed for their electrical properties with MEAs (Microchannel 
Systems, Reutlingen, Germany). MEAs were stored in water and made sterile by 
incubation in hot (>70°C) water and subsequent UV light illumination for up to 1 h. MEAs 
were coated with a small drop of geltrex on the electrode area. IPSC-CMs were digested 




plated in 100 µl cardio-digest medium on the coated MEAs. Cells were allowed to 
regenerate for at least 3 days in cardio-culture medium. Measurements were conducted 
at 37 °C and Iso or Epi were added 1:100 in a cumulative manner to achieve the target 
concentrations. After an equilibration time of 5 min after each drug, electrical signals were 
recorded for 5 min with MC_Rack (Multichannel Systems). For each experiment, one 
electrode with a strong field potential was chosen and beating rates and field potential 
duration (FPD) were extracted from the Data with MC_Rack. Further analysis was carried 
out with Excel (Microsoft Corporation) and data were visualized with GraphPad Prism 
(Graph Pad Software). Frequency corrected FPD (FPDcF) was calculated using 






  (Fridericia, 1920). 
Conduction velocity data were recorded on the MEA system with the software cardio2D 
(Multichannel Systems, Germany) using different catecholamine concentrations. Data 
were analyzed using cardio2D+ software (Multichannel Systems, Germany), MultiElec, 
Excel, and Graph Pad. 
 
3.2.16 Statistical analysis 
 
Data were given as the mean ± SEM (standard error of the mean). The unpaired Student’s 
t-test was used to compare the differences between two independent groups. For 
significance analysis, the multiple t-test, the one-way and two-way ANOVA were used for 
comparison of more groups and conditions and corrected for multiple comparisons. For 
dose-response curves, significances were calculated by extra sum-of-squares F test.  A 
p-value of less than 0.05 was considered statistically significant with *=p<0.05, **=p<0.01 
and ***=p<0.001. Statistical analysis was performed with GraphPad prism. N-numbers 
were defined as differentiation experiments of different cell lines from mentioned 








4.1 Clinical profile of recruited TTS-patients 
 
The patients who were recruited from the Takotsubo registry in Zurich for this study fulfilled 
the Mayo-clinic criteria for TTS. Somatic cells from 7 recruited probands (4 TTS patients 
and 3 controls) were successfully isolated. These subjects had the following clinical 
profiles: 



















LVEF in % NYH
A 
1-TTS 60 Female Emotional 
stress: 
grief and loss 
yes no apical 40 IV 




no no apical 40 I 




no yes apical 40 I 






















LVEF in % NYH
A 




2-C 25 Female - - - - - - 
3-C 25 Female - - - - - - 
iFB2 - Female - - - - - - 
 
The TTS group consisted of four female patients with an age range of 60–72 years. 
Somatic cells of all 4 TTS patients were reprogrammed into iPSCs in this thesis.  Our 
control group consisted of four healthy females aged 25–52 years, from whom somatic 
cells of 3 patients were reprogrammed into iPSCs in this thesis. One of the CTRL-iPSC 
lines (iFB2) already existed in our lab and was described before (Streckfuss-Bömeke et 
al., 2013).  
 
4.2 IPSC production and characterization 
 
4.2.1 Production of iPSCs from fibroblasts and blood PBMCs 
 
Fibroblasts were obtained from proband’s skin punch biopsies by mechanical dissection 
followed by fibroblast outgrowth from the biopsy (Figure 5A). Fibroblasts showed spindle-
shaped morphology (Figure 5A). PBMCs were isolated from full blood samples and 
showed typical round morphology (Figure 5A).  
For the generation of iPSCs, fibroblasts and PBMCs were reprogrammed integration-free 
by using Sendai viruses or episomal plasmids encoding for an enhanced set of 
transcription factors. SOX2, KLF4, L-MYC, LIN28, OCT 3/4, and sh-RNA against P53 
were encoded by the plasmids (Okita et al., 2011). SOX2, KLF4, c-MYC, and OCT3/4 
were transported by the Sendai virus. After four weeks in culture, several iPSC-colonies 
grew from the original cells. The iPSC-clones were selected, mechanically picked, and 
expanded. From each patient and control proband, two cell lines were chosen for 
expansion and characterization. The obtained cell lines were subsequently used for 





4.2.2 IPSCs show stem cell morphology and express pluripotency 
markers 
 
To prove the pluripotency of the produced iPSC-lines, colony morphology, alkaline 
phosphatase expression, and pluripotency marker expression on mRNA and protein 
levels were analyzed.  IPSC-colonies showed a typical ESC-like round morphology and 
were stained positive for alkaline phosphatase (Figure 5B), an enzyme, which is active in 
undifferentiated cells (O’Connor et al., 2008), while feeder cells remained negative (Figure 
5B).  On mRNA-level, the produced iPSCs revealed strong expression of OCT4, NANOG, 
SOX2, LIN28, GDF3, and FOXD3 (Figure 5C). The source fibroblasts and PBMC lines did 
not show such an expression (Figure 5C). At protein level, the nuclear-localized 
transcription factors OCT4, NANOG, SOX2 (Figure 6, red), and the membrane-bound 
pluripotency markers TRA-1-60 and SSEA4 (Figure 6, green) were highly expressed in all 
tested iPSCs. Furthermore, the pluripotency marker LIN28 (Figure 6, red) was found to 
be localized both in the cytoplasm and nucleus of the stained cell lines. No differences in 







Figure 5: Reprogramming of somatic cells to iPSCs: A: Brightfield images of the source material 
for the production of iPSCs. Skin fibroblasts growing out of a skin punch biopsy (left picture). blood 
mononuclear cells (PBMCs) isolated from blood samples (right picture). Scale bars = 100 µm B: 
IPSC-colonies showed a typical ESC-like morphology and were stained positive for alkaline 
phosphatase (ALP) (red). Scale bars = 100 µm C: IPSCs express the pluripotency markers SOX2, 





Figure 6: 5-TTS, 8-TTS, 2-C and 3-C-iPSCs show expression of pluripotency markers on protein 
level. Immunofluorescence staining of OCT4 (red), SOX2 (red), LIN28 (red), TRA-1-60 (green), 
SSEA4 and (green) NANOG (red). Nuclei were stained with DAPI (blue). Scale bars=50 µm. 
 





One key characteristic of pluripotent stem cells is their ability to differentiate into cells of 
the three different germ layers, namely endoderm, mesoderm, and ectoderm. In order to 
confirm this, differentiation tests were carried out in vitro and in vivo. 
For in vitro differentiation, mass culture assays were used. In brief, clumps of iPSCs were 
spontaneously differentiated into all possible directions. IPSCs were grown in aggregates 
in suspension culture for 8 days and then allowed to grow on plates for up to 25 more 
days. The resulting cultures were analyzed via immunofluorescence. On protein levels, 
AFP (red) was detected as an early endodermal marker, β-tubulin (green) as an 





Figure 7: IPSCs differentiated to all three germ layers in vitro and in vivo. A: In vitro differentiated 
cells express the endodermal marker AFP (red), the mesodermal marker α-SMA (green), and the 
ectodermal marker β-tubulin (green). In the case of β-tubulin, cells exhibiting a typical neuronal 
morphology. Nuclei were stained with DAPI (blue). Scale bars: 50 µm. B: In vivo teratoma 
formation shows cells from mesoderm (cartilage, muscle), endoderm (intestine epithelium), and 




In an in vivo teratoma forming assay, the iPSCs were injected into immunosuppressed 
SCID mice. Growing teratomas were explanted (injection and explantation were done by 
Prof. Ralf Dressel) and histologically analyzed for tissue characteristics of the three 
different germ layers. IPSCs were able to differentiate into mesoderm, as shown by the 
formation of cartilage tissue (Figure 7B), endoderm as shown by the formation of intestine 
tissue (Figure 7B) and ectoderm as shown by the formation of neuronal rosettes (Figure 
7B). 
To ensure none of the cells harbored an HIV infection, all cell lines were screened by our 
group. All generated iPSC lines were tested negatively for HIV infection by using a high 
throughput technology in our lab (Hübscher et al., 2019). 
In summary, in this thesis, 4 TTS patients and 3 controls were integration-free 
reprogrammed into iPSC-lines by Sendai virus transduction or plasmid transfection. The 
three iPSC lines (2-C, 5-TTS, 8-TTS) analyzed for pluripotency showed a typical ESC-like 
morphology and expressed alkaline phosphatase. Additionally, the iPSCs showed robust 
expression of pluripotency markers on mRNA and protein levels. Furthermore, the cells 
were able to differentiate into all three germ layers in vitro and in vivo. No relevant 
differences were detected between CTRL- and TTS-iPSCs regarding spontaneous 
differentiation capacity or pluripotency marker expression. Of note, all tested cell lines 
were free of HIV. 
 
4.2.4 IPSCs can be directly differentiated into functional 
cardiomyocytes 
 
To produce iPSC-CMs, targeted Wnt-pathway manipulations were used (Burridge et al., 
2014). To achieve this, the GSK3-inhibitor CHIR was added to the medium for two days 
to achieve mesoderm induction and the Wnt-inhibitor IWP2 was used for additional two 
days to induce cardiomyocyte differentiation. The differentiated cardiomyocytes were 
metabolically selected with lactate to achieve a high purity (Burridge et al., 2014). IPSC-





Figure 8: Cardiac differentiation of iPSCs. A: Differentiated cardiomyocytes express α-actinin 
(green) on protein level as analyzed by immunofluorescence. Nuclei were stained with DAPI 
(blue). Scale bars = 20 µm B: Example of FACS analysis of cTNT-positive cells. Overall, iPSC-
CMs showed a purity of over 80%. C: Differentiated cardiomyocytes express the cardiomyocyte 
markers ACTN2, MYH6, MYH7, and TNNT2 on mRNA level. D: Analysis of the sarcomeric 
structure with fast Fourier transformation (FFT) revealed a regular sarcomeric structure. Left 
picture: α-actinin staining of a cardiomyocyte used for FFT analysis. Middle picture: FFT of the left 
picture. Right picture: Intensity plot of the FFT in the middle shows regular peaks representing 
different sarcomere distances. 
The produced iPSC-CMs exhibited a prominent sarcomeric structure, as shown by α-
actinin staining (Figure 8A, green). To analyze the amount of generated iPSC-CMs, 2-




cytometry. The obtained iPSC-CMs showed a purity of 80–95% (Figure 8B). The 
cardiomyocytes expressed the typical cardiomyocyte markers α-actinin (ACTN2), α-
myosin heavy chain (MYH6), β-myosin heavy chain (MYH7), and cTNT (TNNT2) with 
simultaneous depletion of the pluripotency marker SOX2 and LIN28 on mRNA level 
(Figure 8C). No differences in cardiac marker expression and differentiation capacity were 
observed between CTRL-iPSC-CMs and TTS-iPSC-CMs. Furthermore, the differentiated 
iPSC-CMs showed robust regular beating activity, often in a coordinated manner, 
exhibited strong Ca2+ transients, and regular electrical activity. 
 
4.3 Stress can be induced by the addition of catecholamines 
 
To uncover whether catecholamines can induce stress in iPSC-CMs, they were 
challenged with different catecholamine dosages (iso 100 nM – 5 mM, Epi 100 nM – 500 
µM) and sarcomeric structure and apoptosis were analyzed. 
Our group showed that Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) was 
increased upon Iso stimulation as shown by next-generation sequencing. The same was 
observed in qPCR studies in reaction to Epi and Iso as a consequence of the increase in 
cellular stress. TTS-iPSC-CMs showed a stronger increase of NR4A1 expression in 
response to Iso than CTRL-iPSC-CMs. When challenged with catecholamines, the 
sarcomeric structure, as demonstrated by α-actinin staining, was not disturbed (Figure 
9A).  
To check for cytotoxic effects of high levels of catecholamines, apoptosis was analyzed 
by annexin V/propidium iodide staining and subsequent quantification. Apoptosis levels 
reached around 4% for untreated iPSC-CMs. For iPSC-CMs treated with low (100 nM) or 
high levels (5 mM Iso or 500 µM Epi) of catecholamines (Figure 9B), no significant 
differences to untreated cells were observed. Additionally, no differences were found 
between CTRL-iPSC-CMs and TTS-iPSC-CMs. In summary, Iso and Epi treatment had 





Figure 9: Stress induction in cardiomyocytes by addition of high dosages of catecholamines. A: 
α-actinin staining shows that treatment with high levels of catecholamines did not result in an 
altered sarcomeric structure. Scale bar: 20 µm B: Apoptosis measurements with annexin 
V/propidium iodide (PI) showed no increased apoptosis in catecholamine treated CTRL-iPSC-
CMs (n=4 differentiations: 1-C1 [n=1]), 2-C [n=1] and iFB2 [n=2]) or TTS-iPSC-CMs (n=3 
differentiations: 1-TTS [n=1], 5-TTS [n=1], and 8-TTS [n=1]). Data are presented as mean ± SEM. 
Significances were tested using one-way ANOVA. 
 
4.4 Catecholamines cause electrical disturbances 
 
Earlier experiments from our group revealed different cAMP responses in CTRL-iPSC-
CMs and TTS-iPSC-CMs: CTRL-iPSC-CMs reached maximum cAMP concentrations 
after stimulation with 100 nM Iso, whereas in TTS-iPSC-CMs, cAMP concentration 
reached their peak at Iso dosages of 1 mM (Borchert et al., 2017). To examine whether 
this also causes changes in electrical behavior, multi-electrode arrays were used to 
observe the electrical properties of CTRL-iPSC-CMs and TTS-iPSC-CMs. Therefore, the 




Beating frequency, field potential duration, FPDcF, and cardiac conduction velocity were 
calculated. 
Figure 10A shows some representative MEA traces of CTRL- and TTS-iPSC-CM 
preparations with and without Iso stimulation. Generally, the addition of Iso caused a 
frequency increase as expected. However, some iPSC-CMs reacted with silenced 
electrical activity towards stimulation. Interestingly, the observed silencing effect was very 
acute without strong preceding arrhythmias (Figure 10A). 
TTS-iPSC-CMs reached a frequency maximum at 1 µM and CTRL-iPSC-CMs at higher 
levels of 10 µM. After reaching their maximal frequency, TTS- and CTRL-iPSC-CMs 
showed decreasing beating frequencies at rising Iso concentrations, reaching a minimum 
at Iso levels of 5 mM (Figure 10B). TTS-iPSC-CMs showed a stronger reaction towards 
Iso by exhibiting a significantly increased relative beating frequency compared to CTRL-
iPSC-CMs at 1 µM (3.3-fold±0.3 vs. 2.0-fold±0.3)  and 10 µM (3.3±0.2 fold vs. 2.3±0.3 
fold) (Figure 10C).  
As previously mentioned, some of the cardiomyocytes showed a cessation of beating 
upon Iso addition. In the conducted experiments, TTS-iPSC-CMs were more prone to this 
cessation of beating caused by high levels of Iso than the observed CTRL-iPSC-CMs 
(Figure 10D). Surprisingly, Epi did not cause beating cessation. Removal of Iso and 
recovery of the cells for 2 – 24 h hours led to a reversal of the described effects (Figure 





Figure 10: Multi-electrode arrays uncover electrical differences between TTS- and CTRL-iPSC-
CMs. A: Representative MEA traces of CTRL- and TTS-iPSC-CMs. Of note are the spontaneous 
disruption of beating activity (middle) and the increased beating activity in the non-disrupted iPSC-
CMs (right). B: CTRL-iPSC-CMs (n=8 MEA experiments: 1-C [n = 6], 2-C [n = 1], and iFB2 [n = 1]) 
and TTS-iPSC-CMs (n=7 MEA experiments: 1-TTS [n = 6] and 8-TTS [n = 1]) beating frequency 
under Iso stimulation. C: Normalized beating frequency analysis of CTRL-iPSC-CMs (n=8 MEA 
experiments: 1-C [n = 6], 2-C [n = 1], and iFB2 [n = 1]) and TTS-iPSC-CMs (n=7 MEA 
experiments: 1-TTS [n = 6] and 8-TTS [n = 1]) under Iso stimulation. D: Quantification of silenced 




[n = 2]) and TTS-iPSC-CMs (n=7 MEA experiments: 1-TTS [n = 8] and 8-TTS [n = 3]) after Iso 
challenge presented as a beating survival curve. TTS-iPSC-CMs stopped electrical activity at 
lower Iso dosages than CTRL-iPSC-CMs. All data are presented as mean ± SEM. Significant 
differences were calculated using two-way ANOVA. 
Field potential durations provide information about action potential durations. Analysis of 
the field potential duration (Figure 11A/C) and the FPDcF (algorithm of Frederica) (Figure 
11B/D) revealed no significant differences between TTS and CTRL-iPSC-CMs (Figure 
11). Moreover, FPD decreased upon Iso and Epi treatment (Figure 11A/C). FPDcF stayed 
constant during Iso (Figure 11B) and Epi (Figure 11D) treatment. 
 
Figure 11: Measurement of field potential duration (FPD) and frequency corrected field potential 
durations (FPDcF) with multi-electrode arrays uncover no significant differences between CTRL 
and TTS-iPSC-CMs. A: Field potential durations of CTRL- (n=7 MEAs: 1-C [n = 6], and iFB2 
[n = 1]) and TTS-iPSC-CMs (n=7 MEAs: 1-TTS [n = 6] and 8-TTS [n = 1]) stimulated with Iso. B: 
Frequency corrected field potential durations of CTRL- (n=7 MEAs: 1-C [n = 6], and iFB2 [n = 1]) 
and TTS-iPSC-CMs (n=7 MEAs: 1-TTS [n = 6] and 8-TTS [n = 1]) challenged with Iso. C: Field 
potential durations of CTRL- (n=8 MEAs: 1-C [n = 6] and iFB2 [n = 2]) and TTS-iPSC-CMs (n=6 
MEAs: 1-TTS [n = 4] and 8-TTS [n = 2]) stimulated with Epi. D: Frequency corrected field potential 
durations of CTRL- (n=8 MEAs: 1-C [n = 6] and iFB2 [n = 2]) and TTS-iPSC-CMs (n=6 MEAs: 1-
TTS [n = 4] and 8-TTS [n = 2]) challenged with Epi. Data are presented as mean ± SEM. 





To examine whether electrical coupling between iPSC-CMs is aberrant, conduction 
velocity measurements were carried out. Conduction velocity was calculated using cardio 
2D and Multi Elec by analyzing the time differences between maximum peaks at different 
electrodes.  
Figure 12A shows an example heatmap of the electrical activation on the MEA. The 
electrical signal travels from one or more pacemakers through the whole MEA surface in 
9 ms. The time and space differences were used in the velocity calculations. Under basal 
conditions the conduction velocity was reduced in TTS-iPSC-CMs (4.97 cm/s) compared 
to CTRL-iPSC-CMs (11.42 cm/s) (Figure 12B). Despite the different velocities, no obvious 
disturbances in conduction were observed (Figure 12B). When challenged with 
catecholamines, conduction velocity did not change significantly (Figure 12C/D/E/F). 
Interestingly, the observed basal differences remained as a trend throughout the 





Figure 12: Measurements of conduction velocities with multi-electrode arrays. A: Representative 
conduction velocity map of a non-stimulated CTRL-iPSC-CM preparation. Colors indicate the 
timepoint of activation at a certain electrode (from red (early) to blue (late)). Lines represent zones, 
which are active at the same time. Arrows indicate the direction of the signal propagation. B: Basal 
conduction velocities of CTRL- (n=4 MEA experiments: 2-C [n=4]) and TTS-iPSC-CMs (n=6 MEA 




conduction velocity than TTS-iPSC-CMs. Significance was calculated using Student’s t-test. C: 
Conduction velocities of Iso stimulated CTRL- (n=3 MEA experiments: 2-C [n=3]) and TTS-iPSC-
CMs (n=3 MEA experiments: 5-TTS [n=2], and 8-TTS [n=1]). D: Conduction velocities of Epi 
stimulated CTRL- (n=2 MEA experiments: 2-C [n=2]) and TTS-iPSC-CMs (n=3 MEA experiments: 
5-TTS [n=2], and 8-TTS [n=1]). E: Normalized conduction velocities of Iso stimulated CTRL- (n=3 
MEA experiments: 2-C[n=3]) and TTS-iPSC-CMs (n=3 MEA experiments: 5-TTS [n=2], and 8-TTS 
[n=1]).  F: Normalized conduction velocities of Epi stimulated CTRL- (n=2 MEA experiments: 2-C 
[n=2]) and TTS-iPSC-CMs (n=3 MEA experiments: 5-TTS [n=2], and 8-TTS [n=1]).  Data are 
presented as mean ± SEM. Sign Significances were calculated using unpaired Student’s t-test (B) 
and two-way ANOVA (C-F). 
 
4.5 Ca2+ handling is different in TTS-iPSC-CMs 
 
To find out whether TTS-iPSC-CMs and CTRL-iPSC-CMs show differences in Ca2+ 
handling, Ca2+ imaging with fluo-4-am was performed. Figure 13 shows typical Ca2+ traces 
and fluorescence intensities of TTS- and CTRL-iPSC-CMs. 
 
Figure 13: Ca2+ imaging recordings of CTRL-iPSC-CMs and TTS-iPSC-CMs. The upper part 
shows original line scans of single cells where the brightness corresponds to calcium (Ca2+) 
concentrations. The lower part shows fluorescence intensities over time and the typical waves 
caused by calcium influx and efflux. T50 marks the half-maximal decay time of the calcium 
transient. 
T50 indicates the half-maximal decay time of the Ca2+ transient and is influenced mainly 
by the activity of the SERCA and NCX pumps. TTS-iPSC-CMs showed a significantly 




Iso (Figure 14A). When normalized, the difference in T50 between CTRL- and TTS-iPSC-
CMs was lower because of the high basal differences (Figure 14B). TTS- and CTRL-iPSC-
CMs showed a significant decrease in T50 times in response to rising Iso dosages (Figure 
14B). TTS-iPSC-CMs showed a reduced T50 time at 100 nM Iso or higher, whereas CTRL-
iPSC-CMs needed 1 µM Iso to achieve a significant reduction (Figure 14B). Interestingly, 
CTRL-iPSC-CMs and TTS-iPSC-CMs exhibit a reduction of T50 even at high Iso dosages 
up to 5 mM (Figure 14B). Supplemental Figure 1 shows normalized T50 for individual 
patients uncovering that some probands reacted stronger (3-C, 8-TTS) towards Iso, while 





Figure 14: Ca2+ measurements of CTRL- and TTS-iPSC-CMs reveal Ca2+ handling differences. 
A: Analysis of half maximal decay times (T50) show a reduction in TTS-iPSC-CMs (n = 148 cells: 
2-TTS [n = 26], 5-TTS [n = 60], and 8-TTS [n = 62]) compared to CTRL-iPSC-CMs (n = 153 cells: 
2-C [n = 47], 3-C [n = 67], and iFB2 [n = 39]) at basal levels and after Iso addition. B: Normalized 
T50 times in CTRL- (n = 153 cells: 2-C [n = 47], 3-C [n = 67], and iFB2 [n = 39]) and TTS-iPSC-
CMs C: Rise time of the Ca2+ transient is increased in TTS-iPSC-CMs (n = 148 cells: 2-TTS [n = 
26], 5-TTS [n = 60], and 8-TTS [n = 62]) compared to CTRL-iPSC-CMs (n = 153 cells: 2-C [n = 
47], 3-C [n = 67], and iFB2 [n = 39]). D: Normalized rise times of CTRL- and TTS-iPSC-CMs (n = 
148 cells: 2-TTS [n = 26], 5-TTS [n = 60], and 8-TTS [n = 62]). E, F: Transient height (F/F0) is 
increased in TTS-iPSC-CMs (n = 148 cells: 2-TTS [n = 26], 5-TTS [n = 60], and 8-TTS [n = 62]) in 




Data are presented as mean ± SEM. Significances were calculated with two-way ANOVA (A, C, 
E) or one-way ANOVA (B, D, F). 
 
 
Rise time specifies the time that is needed to reach the maximum Ca2+ concentration in a 
cardiomyocyte, which is mainly influenced by the activity of the L-type Ca2+ channel and 
the RyR2. TTS-iPSC-CMs exhibited a higher rise time compared to CTRL-iPSC-CMs 
under basal conditions (Figure 14C) and all tested Iso concentrations (Figure 14C). 
Interestingly, the addition of Iso to CTRL-iPSC-CMs and TTS-iPSC-CMs did not cause a 
significant decrease in rise time. However, a trend towards a reduction was observed for 
normalized rise times (Figure 14D).  
Ca2+ transient amplitude (F/F0) provides information about the amount of Ca2+ influx in 
comparison to basal Ca2+ levels. TTS-iPSC-CMs exhibited a higher amplitude at basal 
levels and Iso 100 nM (Figure 14E, F). Interestingly, only CTRL-iPSC-CMs showed a 
robust increase in maximal amplitude when cells were stimulated with Iso. This effect was 
not seen in TTS-iPSC-CMs.  CTRL- and TTS-iPSC-CMs showed a decrease in Ca2+-
transient amplitude at higher Iso dosages. 
 
4.6 TTS-iPSC-CMs did not exhibit an increased Ca2+ leakage 
 
Ca2+ leakage is a hallmark of many cardiac diseases. Therefore Ca2+ sparks were 
analyzed. Figure 15A shows exemplified line scans of CTRL- and TTS-iPSC-CMs with 
Ca2+ sparks. Spark properties were analyzed for FWHM, FDHM, and Amplitude, which 
were used for total Ca2+ leak calculation (Figure 15B). For basal conditions and under Iso 
stimulation (100 nM), no differences in spark numbers were observed between CTRL- 
and TTS-iPSC-CMs. CTRL-iPSC-CMs showed a higher spark frequency at Iso dosages 
of 1 µM and 5 mM Figure 15C. For FWHM (Figure 15D) and FDHM (Figure 15E), no 
significant differences were observed between CTRL- and TTS-iPSC-CMs. The overall 
total calcium leak did not show differences between CTRL- and TTS-iPSC-CMs for basal 
as well as for all tested Iso conditions (Figure 15F). In total, Ca2+ leakage differences were 






Figure 15: Ca2+ spark analysis. A: Example line scans with Ca2+ sparks of CTRL- and TTS-iPSC-
CMs. B: 3D rendering of a Ca2+ spark with the relevant size parameters. C: Spark frequency of 
CTRL- (n = 30 cells: 3-C [n=30 cells, black and blue dots for 2 differentiations]) and TTS-iPSC-
CMs (n = 57 cells: 5-TTS [n=30, black dots and blue dots for 2 differentiations], 8-TTS  [n=27, 
black triangles and blue triangles for 2 differentiations]) under Iso stimulation. D: Full width at half 




differentiations]) and TTS-iPSC-CMs (n = 57 cells: 5-TTS [n=30, black dots and blue dots for 2 
differentiations], 8-TTS  [n=27, black triangles and blue triangles for 2 differentiations]) under Iso 
stimulation. E: Full duration at half maximum (FDHM) of CTRL- (n = 30 cells: 3-C [n=30 cells, 
black and blue dots for 2 differentiations]) and TTS-iPSC-CMs (n = 57 cells: 5-TTS [n=30, black 
dots and blue dots for 2 differentiations], 8-TTS [n=27, black triangles and blue triangles for 2 
differentiations]) under Iso stimulation. F: Total calcium leak of CTRL- (n = 30 cells: 3-C [n=30 
cells, black and blue dots for 2 differentiations]) and TTS-iPSC-CMs (n = 57 cells: 5-TTS [n=30, 
black dots and blue dots for 2 differentiations], 8-TTS [n=27, black triangles and blue triangles for 
2 differentiations]) under Iso stimulation. Data are presented as mean ± SEM. Significances were 
calculated using two-way ANOVA. 
4.7 Engineered heart muscles reveal a higher sensitivity of 
TTS-iPSC-CMs towards Iso stimulation and decreased β-AR 
desensitization 
 
To obtain a clearer picture of the TTS model in a 3D environment, engineered heart 
muscles from TTS- and CTRL-iPSC-CMs were created and analyzed (cooperation with 
the Department of Pharmacology, University Medical Center Göttingen). The CMs were 
mixed with collagen and wildtype fibroblasts at a 70/30 ratio to create the engineered heart 
muscles (EHMs). EHMs were created and analyzed by Dr. Malte Tiburcy and Dr. Norman 
Liaw (Figure 16). When challenged with Iso, the TTS-iPSC-EHM showed a significantly 
higher sensitivity compared to CTRL-iPSC-EHM, as shown by a lower EC50 (6 ± 1 nM vs. 
13 ± 2 nM) (Figure 16A). Blockage of the β1- and β2-ARs with CGP and ICI increased the 
EC50 values and removed all EC50 differences (Figure 16A). Additionally, beating 
frequency changes after 24 h of Iso stimulation were higher in TTS-iPSC-EHM compared 
to CTRL-iPSC-EHM (Figure 16B) (222% ± 32% vs. 59% ± 19%), which is in line with the 
reported frequency differences in the MEA measurements. After 24 h of Iso pre-
stimulation, the observed EC50 differences were even higher than before as a sign of solid 
β-AR desensitization with CTRL-iPSC-EHM (EC50: 64 ± 10 nM)  exhibiting a stronger EC50 
increase than TTS-iPSC-EHM (EC50: 19 ± 4 nM)  (Figure 16C). Interestingly, TTS-iPSC-
EHM showed a lower force development than CTRL-iPSC-EHM without catecholamine 






Figure 16:  Engineered heart muscles (EHM) uncover an enhanced sensitivity towards Iso of TTS-
iPSC-CMs. A: Dose-response curves of CTRL- and TTS-iPSC-EHM towards increasing dosages 
of Iso. TTS-iPSC-EHM (grey line, n=10 EHM: 1-TTS [n=3], 8-TTS [n=7]) exhibited a lower EC50 
concentration than CTRL-iPSC-EHM (black line, n=11 EHM: 2-C [n=4 EHM], iFB2 [n=7]). After 24 
h Iso pre-stimulation, TTS-iPSC-EHM (orange line, n=7 EHM: 1-TTS [n=3], and 8-TTS [n=4]) again 




iFB2 [n=3]). Addition of CGP and ICI (black dashed lines=CTRL, n=4 EHM: iFB2 [n=4], grey 
dashed lines=TTS, n=4 EHM: 8-TTS [n=4]) blocked all EC50 differences. B: Change in beating 
frequency of EHM after 24 h Iso stimulation. TTS-iPSC-EHM (n=7 EHM: 1-TTS [n=3], and 8-TTS 
[n=4]) show a higher increase in beating frequency than CTRL-iPSC-EHM (n=5 EHM: 2-C [n=2], 
and iFB2 [n=3]). C: EC50 increase after Iso preincubation (1 µM) for 24 h. CTRL-iPSC-EHM (EHM 
from Figure 16A were analyzed) showed a stronger increase of EC50 after 24 h Iso preincubation 
than TTS-iPSC-EHM (EHM from Figure 16A were analyzed). D: Force development of EHMs at 
different Ca2+ concentrations. TTS-iPSC-EHM (n=14 EHM: 1-TTS [n=3], 8-TTS [n=11]) showed a 
lower force development than CTRL-iPSC-EHM (n=15 EHM: 2-C [n=4], and iFB2 [n=11]). Data 
are presented as mean ± SEM. Differences were compared by extra sum-of-squares F test (A), 
Student’s t-test (B), one-way ANOVA (C), or two-way ANOVA (D). 
 
4.8 TTS cells demonstrated lipid accumulation 
 
Cardiac adrenergic stimulation regulates lipid metabolism by influencing the PKA pathway 
and NR4A1 induction (Maxwell et al., 2005; Shao et al., 2013). Additionally, experiments 
in our group uncovered a higher NR4A1 increase in TTS-iPSC-CMs in comparison to the 
CTRL-iPSC-CMs when stimulated with Iso (Borchert et al., 2017). Therefore, lipid 
accumulation was analyzed in catecholamine-treated iPSC-CMs by Oil Red O staining. 
Lipid staining revealed only minor lipid accumulation in untreated cells. After Epi addition, 
lipid droplets were increased in TTS-iPSC-CMs. No lipid accumulation was observed in 
CTRL-iPSC-CMs (Figure 17A/B, lipid accumulations are indicated by white arrows). The 
droplet amount did increase 5.0 to 5.7-fold for 100 nM or 500 µM Epi, respectively (Figure 
17B). Interestingly, no significant lipid droplet increase was observed in Iso-treated iPSC-
CMs (Figure 17B). 
Based on the obtained data, the expression of different lipid transporters was analyzed. 
The lipid importer CD36 expression was significantly increased on mRNA level (Figure 
17C) in TTS-iPSC-CMs already at basal levels and under Epi 500 µM stimulation arguing 
for a higher lipid import into these cells. During Epi stimulation, no CD36 expression 
changes were observed in CTRL- and TTS-iPSC-CMs. In line with the observed lipid 
accumulation, there was a decreased mRNA expression of the lipid translocase CPT1C 
in TTS-iPSC-CMs compared to CTRL-iPSC-CMs for Iso 100 nM, Epi 100 nM, and Epi 500 






Figure 17: TTS-iPSC-CMs show lipid accumulation and differentially expressed lipid transporters. 
A: Lipid accumulation after catecholamine stimulation for 2 h in CTRL- and TTS-iPSC-CMs was 
visualized by Oil Red O staining. Lipid droplets are depicted by arrows. B: Quantification of the Oil 
Red O lipid accumulation. TTS-iPSC-CMs (n = 4 to 14 images: 1-TTS [n = 3 to 9], 8-TTS [n = 1 to 
7]) showed a prominent increase under Epi stimulation and a moderate increase after Iso 
stimulation compared to CTRL-iPSC-CMs (n = 3 to 9 images: 1-C [n = 2 to 8], iFB2 [n = 3]). 
Differences between the groups were compared using one-way ANOVA. C, D: mRNA expression 
of the lipid importer CD36 was increased and expression of the lipid translocator CPT1C was 
decreased in TTS-iPSC-CMs (n = 7 differentiation experiments: 1-TTS [n = 3] and 8-TTS [n = 4]) 
compared to CTRL-iPSC-CMs (n = 7 differentiation experiments: 1-C [n = 3], 2-C [n = 2], and iFB2 





4.9 Inhibition of selected β-pathways uncovers the role of 
different β-AR sub-receptors 
 
To dissect the influence of the different β-ARs in cardiomyocytes, the β1-specific inhibitor 
CGP was used at a concentration of 100 nM and the β2-specific inhibitor ICI was used at 
a concentration of 50 nM in combination with catecholamine stimulation. As the heart 
mainly expresses β1- and β2-ARs, blockage of one of these receptors uncovers the 
influence of the other. A combination of CGP and ICI was used to assess the behavior of 
the two receptors, when both dominant β-ARs were silenced. 
 
4.9.1 MEA measurements emphasize the roles of different β-ARs in 
TTS-iPSC-CMs 
 
MEAs were used to analyze the inherent beating frequency of the CTRL-iPSC-CMs and 
TTS-iPSC-CMs under the influence of the different β-AR subtype-specific β-blockers in 
combination with increasing levels of catecholamines. 
CTRL-iPSC-CMs and TTS-iPSC-CMs exhibited increasing beating frequencies under Iso 
treatment, as shown before (Figure 10, Figure 18A-D). In CTRL-iPSC-CMs, a combination 
of CGP and ICI was able to significantly suppress the beating frequency increase at Iso 
concentrations of 100 nM and 1 µM in comparison to Iso-stimulated CTRL-iPSC-CMs 
without β-AR inhibitors (Figure 18A/C, purple line). Higher Iso concentrations caused a 
frequency increase. At Iso concentrations of 1mM, frequencies of CTRL-iPSC-CMs of all 
conditions reached the same level (Figure 18A/C). Overall, CTRL-iPSC-CMs treated with 
CGP showed no significant differences in frequency upregulation in response towards Iso 
in comparison to cells not treated with β-AR-blockers (Figure 18A/C, blue line). In contrast, 
when CTRL-iPSC-CMs were treated with ICI, the frequency upregulation was significantly 
lower at 100 nM Iso compared to untreated cells (Figure 18A/C, red line). These findings 






Figure 18: Influence of selective β-inhibition on electrical behavior of CTRL- and TTS-iPSC-CMs. 
A, B: Iso dose-dependent frequency increase under influence of CGP, ICI or CGP+ICI for CTRL-
iPSC-CMs (n=3 MEA experiments: 2-C [n=2], iFB2 [n=1]) vs TTS-iPSC-CMs (n=3 MEA 
experiments: 2-TTS [n=1], 5-TTS [n=1], 8-TTS [n=1]). C, D: Normalized Iso dependent frequency 
increase under influence of CGP, ICI, or a combination thereof. In CTRL-iPSC-CMs (same MEA 
experiments as in A/B), β2-inhibition by ICI caused a significant decrease in the beating rate. In 
TTS-iPSC-CMs (same MEA experiments as in A/B), both β-ARs seem to play a significant role. 
The use of both inhibitors caused a strong decrease in the frequency compared to no inhibitor as 
expected. Data are presented as mean ± SEM. Differences between each β-inhibitor combination 




In TTS-iPSC-CMs, only the combination of CGP and ICI produced a significant effect in a 
similar way to CTRL-iPSC-CMs, resulting in a lower frequency for this treatment compared 
with TTS-iPSC-CMs treated only with Iso (Figure 18B/D). CGP or ICI treatment alone was 
not able to produce a significant effect. A trend towards lower frequencies, however, was 
visible (Figure 18B/D). This finding suggests that both β-ARs are important in TTS-iPSC-
CMs. 
 
4.9.2 Ca2+ measurements support the dominant role of β2-ARs in 
CTRL-iPSC-CMs and β1-ARs in TTS-iPSC-CMs 
 
To check whether the different β-AR subtypes also influence Ca2+ signaling, CGP and ICI 
were used as described above. Additionally, Iso was used to stimulate the cardiomyocytes 
and Ca2+ cycling was measured and normalized T50 and rise times were analyzed. 
Without inhibitors, T50 times were reduced as described (Figure 14A). Blockage of both β-
ARs was able to block a T50 reduction for Iso dosages below 1 mM for CTRL- and TTS-
iPSC-CMs (Figure 19A). Without Iso stimulation, the addition of CGP and ICI caused a 
reduction of T50 times in CTRL-iPSC-CMs (Supplemental Figure 2). Relative T50 analysis 
uncovered that CGP-treated CTRL-iPSC-CMs showed a significantly reduced T50 time at 
Iso concentrations of 1 µM, whereas CTRL-iPSC-CMs treatment with ICI showed the 
same effect for much higher Iso concentrations (5 mM) (Figure 19A). As expected, the 
addition of CGP and ICI suppressed all T50 reductions caused by Iso in CTRL-iPSC-CMs 
(Figure 19A). 
In TTS-iPSC-CMs, at basal conditions, blockage of the β2-AR with ICI caused an increase 
in T50 (Supplemental Figure 2).  Treatment with the β1-AR antagonist CGP abolished all 
T50 reductions caused by Iso treatment of all concentrations (Figure 19A). When treated 
with the β2-AR antagonist ICI, 100 nM Iso was not enough to cause a significant decrease 
of T50. However, stimulation with higher Iso dosages from 1 µM, 1 mM, and 5 mM resulted 
in a significant decrease in relative T50 times. CGP and ICI together were able to suppress 




The addition of CGP or ICI without Iso caused an increase in rise time in CTRL-iPSC-CMs 
(Supplemental Figure 2). When challenged with CGP, CTRL-iPSC-CMs showed a 
reduced rise time under Iso stimulation from 1 mM to 5 mM (Figure 19B). No rise time 
reduction was observed when cells were challenged with ICI and Iso (Figure 19B). When 
CTRL-iPSC-CMs were treated with CGP and ICI together, different Iso dosages were not 
able to significantly reduce the rise time (Figure 19B). Without Iso stimulation, the addition 
of CGP caused a decrease of rise time in TTS-iPSC-CMs and the addition of ICI caused 
an increase in rise time (Supplemental Figure 2). Blockage of the β1-AR with CGP and a 
subsequent challenge of Iso did not cause a reduction of the rise time in TTS-iPSC-CMs 
(Figure 19B). In contrast, the addition of ICI and Iso to TTS-iPSC-CMs caused a reduction 
of rise time at Iso concentrations from 100 nM to 5 mM (Figure 19B). Co-stimulation with 
CGP and ICI, together with Iso, did not result in a reduction of rise time (Figure 19B).  
In conclusion, these findings further support the hypothesis that β2-AR plays an important 
role in CTRL-iPSC-CMs. Furthermore, they strengthen the additional important role of the 
β1-ARs in TTS-iPSC-CMs. However, they also show that both β-ARs contribute to full 









Figure 19: Selective β-inhibition with CGP and ICI uncover different roles of β1- and β2-ARs in 
CTRL- and TTS-iPSC-CMs. A: Normalized T50 times of CTRL- (69 cells: 2-C [n=25], 3-C [n=22], 
iFB2 [n= 22]) and TTS-iPSC-CMs (73 cells: 2-TTS [n=26], 5-TTS [n=24], 8-TTS [n= 23]) treated 
with CGP, ICI or CGP + ICI in combination with Iso. β2-ARs seem to play an important role in 
CTRL-iPSC-CMs and β1-ARs in TTS-iPSC-CMs. Data are presented as mean ± SEM and 
compared using one-way ANOVA. B: Normalized rise time measurements with CGP, ICI, or CGP 
+ ICI in combination with Iso. Again, β2-ARs were engaged in response to Iso stimulation in CTRL-
iPSC-CMs (same cells as in A), whereas β1-ARs are important in TTS-iPSC-CMs (same cells as 
in A). Addition of CGP and ICI blocked all rise time reductions caused by Iso. Data are presented 












Takotsubo syndrome is a severe heart disease triggered by excessive emotional or 
physical stress. These high-stress levels cause the release of high concentrations of 
catecholamines in the circulation, which may result in partial heart failure by left ventricular 
apical dyskinesia and basal hyperkinesia. Symptoms resulting from TTS are similar to 
those in patients with MI. It is commonly treated with a wide range of drugs like ACE-
inhibitors, β-blockers, heparin, and ASS in combination with intensive care (Ghadri et al., 
2018b; Templin et al., 2015). Interestingly, after surviving the initial event, heart function 
recovers over the course of days to weeks. Unfortunately, a TTS attack increases the risk 
for future adverse cardiovascular diseases like heart attack and stroke. In consequence, 
the 5-year survival rate of TTS is similar to that of an acute STEMI (Templin et al., 2015). 
Thus, it is of utmost importance to learn more about this cryptic disease.  
Not much is known about the causes and the pathomechanisms of TTS. However, with 
some hints towards a genetic component, modeling of Takotsubo syndrome with iPSC-
CMs could shed light on the pathophysiology of the disease. This work demonstrates the 
feasibility of a human TTS model based on iPSC-CMs to experimentally study TTS using 
cell culture techniques. 
To this end, fibroblasts or PBMCs from four different TTS patients and three control 
probands were successfully reprogrammed to iPSCs using integration-free methods 
including Sendai viruses or gene transfection with plasmids. The resulting iPSCs 
expressed typical pluripotency-related genes at mRNA and protein level. The cells could 
be readily differentiated into cells from all three different germ-layers in vitro expressing 
germ-layer-specific genes at both mRNA and protein levels. Furthermore, the generated 
iPSCs differentiated in vivo in the form of teratomas showing properties of endodermal, 
mesodermal, and ectodermal tissues. In summary, the produced iPSCs showed the same 
attributes as hESCs and can be considered pluripotent.  
The iPSCs were then differentiated into iPSC-CMs with the help of Wnt-pathway 




CMs showed a purity of more than 80% to 95 %, as measured by flow cytometry with 
antibodies against cTnT. The produced iPSC-CMs showed spontaneous beating activity, 
expressed cardiomyocyte-specific genes ACTN2, MYH6, MYH7, and TNNT2 on mRNA 
and cTnT and α-actinin on protein level. No difference in sarcomeric structure organization 
was observed. Furthermore, the CTRL- and TTS-iPSC-CMs showed electrical coupling 
and coordinated beating activity. Additionally, the cells could be paced electrically and 
showed regular Ca2+ waves typical for cardiomyocytes. 
Treatment of iPSC-CMs with increasing catecholamine levels was carried out to mimic 
the TTS situation and analyzed for apoptosis, electrical activity Ca2+ homeostasis, 
behavior in a 3D-EHM system, and lipid accumulation. High Iso treatment did not induce 
significant levels of apoptosis. When stimulated with rising levels of Iso, CTRL-iPSC-CMs 
and TTS-iPSC-CMs stopped spontaneous electrical activity, with TTS-iPSC-CMs being 
more prone towards this effect. Additionally, TTS-iPSC-CMs showed a stronger frequency 
increase upon Iso stimulation. The conduction velocity was reduced in TTS iPSC-CMs in 
comparison to CTRL-iPSC-CMs. Ca2+ handling differed between TTS-iPSC-CMs and 
CTRL-iPSC-CMs were present on multiple levels. Under basal conditions, times to 50% 
decay were shorter, and rise times were longer in TTS-iPSC-CMs in comparison to CTRL-
iPSC-CMs. The observed differences persisted under Iso stimulation, which caused a 
general T50 reduction. CTRL-iPSC-CMs showed a higher spark frequency at higher Iso 
levels (1 µM), but overall there was no difference in total Ca2+ leakage. In 3D EHM, iPSC-
EHM from cell isolates obtained from TTS patients showed a significantly higher sensitivity 
compared to CTRL-iPSC-EHM when challenged with Iso, as shown by a lower EC50. After 
24 h Iso pre-stimulation, the observed EC50 differences were even higher than before, 
with CTRL-iPSC-EHM exhibiting stronger β-AR desensitization than TTS-iPSC-EHM. 
Additionally, changes in beating frequency after 24 h Iso stimulation were more prominent 
in TTS-iPSC-EHM compared to CTRL-iPSC-EHM, which is in line with the reported 
frequency differences in the MEA measurements. Interestingly, TTS-iPSC-EHM showed 
a lower force development than CTRL-iPSC-EHM without catecholamine stimulation. The 
TTS-iPSC-CMs exhibited higher lipid accumulation in comparison to CTRL-iPSC-CMs, 




The selective β-blockers CGP and ICI were used to uncover the roles of different β-ARs 
in CTRL- and TTS-iPSC-CMs during electrical analysis and Ca2+ cycling. CTRL-iPSC-
CMs showed stronger Iso effects under CGP-based β1-AR inhibition in T50 times and rise 
times. When TTS-iPSC-CMs were treated with ICI, Iso stimulation caused significant 
decreases in relative T50 times and rise times. MEA experiments demonstrated that, under 
β2-AR blockage, CTRL-iPSC-CMs showed a reduced response towards Iso stimulation. 
These findings underpin an important role of β2-ARs in CTRL-iPSC-CMs and β1-ARs in 
TTS-iPSC-CMs.  
Overall, TTS-iPSC-CMs and TTS-iPSC-EHM reacted stronger towards Iso stimulation 
and exhibited a pronounced β1-AR reaction in comparison to CTRL-iPSC-CMs. 
Furthermore, TTS-iPSC-CMs showed differences versus CTRL-iPSC-CMs even without 
Iso stimulation, suggesting a fundamental difference to CTRL-iPSC-CMs, which could be 
caused by a genetic predisposition in TTS. 
 
5.1 Stimulation with Iso did not induce significant levels of 
apoptosis 
 
Here, it was shown that treatment of TTS-IPSC-CMs with high catecholamine 
concentrations did not induce significantly different levels of apoptosis compared to 
untreated CTRL-iPSC-CMs. This suggests that the catecholamine levels used in this 
study are not able to activate acute apoptosis in cardiomyocytes. This observation is in 
line with the fact that β-ARs stimulated by catecholamines can activate Gi proteins 
(Heubach et al., 2004; Paur et al., 2012) and may modulate myocardial damage during a 
catecholamine crisis. In TTS patients, PI3K expression was elevated and AKT 
phosphorylation was increased, thereby possibly contributing to a cellular protective 
mechanism (Nef et al., 2009a). It was found by our group as well as several others that β-
AR stimulation increases NR4A1-expression (Borchert et al., 2017; Medzikovic et al., 
2015; Yan et al., 2015). Additionally, our group demonstrated a higher response of NR4A1 
towards Iso in TTS-iPSC-CMs compared to CTRL-iPSC-CMs (Borchert et al., 2017). You 




latexin-3 and suppresses Iso-induced apoptosis (You et al., 2018). The high expression 
of NR4A1 in CTRL- and TTS-iPSC-CMs is in line with these findings. Concerning the 
patient situation, it must be stated that cardiac biomarkers like troponin are elevated during 
a TTS event suggesting cell damage (Templin et al., 2015). However, the increase of 
elevated troponin is usually lower in TTS than in STEMI(Ghadri et al., 2018b). 
 
5.2 Iso stimulation of iPSCs causes lipid accumulation 
 
The TTS-iPSC-CMs exhibited higher lipid accumulation after catecholamine treatment in 
comparison to CTRL-iPSC-CMs. These findings are in line with observations from a study 
by Shao et al., demonstrating lipid accumulation upon Iso exposure in human cardiac 
biopsies and the HL-1 cardiomyocyte cell line (Shao et al., 2013). Furthermore, the same 
group demonstrated that patients’ serum was able to induce the same effect as Iso (Shao 
et al., 2013). The results are underpinned by higher expression of the CD36 lipid 
transporter and reduced expression of CPT1C lipid translocase in TTS-iPSC-CMs by our 
group. Additionally, Jodalen and coworkers demonstrated an extensive formation of 
intracellular lipid droplets and serum fat accumulation in mice treated with Iso, concordant 
to the results in this work (Jodalen et al., 1982). Interestingly, excess intracellular lipids in 
cardiomyocytes can activate protein kinase C and cause β-AR downregulation, resulting 
in reduced cAMP levels (Drosatos et al., 2011). Based on these results, one could argue 
that β-response in TTS-iPSC-CMs would decrease with time, when the cells accumulate 
higher amounts of lipids. This was not observed in the obtained iPSC-EHM results 
showing a lower EC50 increase towards Iso after 24 h Iso pre-stimulation in TTS-iPSC-
CMs and, therefore, lower β-AR desensitization. The change in beating frequency after 
24h iso pre-stimulation was bigger in TTS-iPSC-CMs and is not in line with the lower 
cAMP level results of Drosatos and colleagues. Future experiments would focus on the 
combination of TTS patients’ serum and TTS-iPSC-CMs to replicate the results of Shao 
et al. using our model and identify potential contributing factors. Additionally, Förster 
resonance energy transfer (FRET) analysis of Iso pre-stimulated iPSC-CMs would shed 





5.3 Electrical activity analysis shows that TTS-iPSC-CMs 
react stronger towards Iso than CTRL-iPSC-CMs 
 
The TTS-iPSC-CMs and CTRL-iPSC-CMs showed significant electrophysiological 
differences on many levels.  
When stimulated with rising levels of catecholamines, TTS-iPSC-CMs and CTRL-iPSC-
CMs stopped spontaneous electrical activity. However, the catecholamine levels needed 
for TTS-iPSC-CMs to achieve this effect were lower than in CTRL-iPSC-CMs. This 
behavior is in line with the theory of an increased susceptibility towards the negative 
effects of catecholamines in cells from individuals with TTS. This behavior can be 
interpreted as cardiac stunning and therefore mimics the behavior of ventricular 
dysfunction observed in TTS-patients (Templin et al., 2015). In parallel to TTS patients, 
electrical silent iPSC-CMs showed beating recovery 1 h to 24 h after the removal of 
catecholamines. The observed recovery was significantly faster than in vivo and occurs 
in the timescale of hours compared to days in actual patients. In line with our findings, a 
significantly faster recovery was also seen in in vivo rat experiments with catecholamines 
being administered from an external source (Paur et al., 2012). In a retrospective study, 
ejection fraction recovery time in TTS was found to be 25 days (Shaikh et al., 2018). 
Interestingly, in the same study, a high variability in recovery times was noted (Shaikh et 
al., 2018). A long recovery time was also seen by Lee and colleagues, who found 
improvements in the ejection fraction up to 5 weeks after hospital discharge (Lee, 2020). 
The rapid recovery in the iPSC-CMs might be in part due to the fast and thorough removal 
of catecholamines in the artificial system, whereas, in patients, catecholamine levels stay 
high for longer durations. This has been demonstrated by Christensen et al., who found 
that TTS patients still had increased plasma Epi levels at 100 days after their admission 
compared to controls (Christensen et al., 2016). One could also speculate that 
catecholamine levels in TTS patients are on a higher basal level.  
As expected, rising catecholamine concentrations caused an increased beating 




increase in the beating frequency was observed in TTS-iPSC-CMs in comparison with 
CTRL-iPSC-CMs. It was shown that TTS patients had significantly increased heart rates 
in comparison to acute MI patients, which is in line with our results (Templin et al., 2015). 
The importance of a high heart rate in TTS was also underpinned by a study of Ali and 
colleagues who showed that pharmacological suppression of the sinoatrial node was able 
to ameliorate a TTS-like phenotype, which was induced by bolus Iso injection in rats (Ali 
et al., 2020). Concerning the comparability of our results, Wells and colleagues used 
human iPSC-CMs in a comparative study using MEAs (Wells et al., 2019). Stimulation 
with 1 µM Iso resulted in a frequency increase of 50% for 44-day-old iPSC-CMs, which is 
in the same range as the CTRL-iPSC-CMs in this work (100% increase). Surprisingly, 69-
day-old iPSC-CMs were nearly unresponsive towards Iso, at least in part, contradicting 
the results observed in this work (Wells et al., 2019). Additionally, their observed basal 
frequencies were higher, being in the range of 2 Hz in 2-month-old iPSC-CMs compared 
to 0.5 Hz in this work. In another publication, which used less than one-month-old hESC-
CMs frequencies of 0.3 Hz to 1 Hz were found (Zhu et al., 2017). Furthermore, heart rates 
in non-stressed humans are typically in the range of 1 Hz, being in the same range as the 
iPSC-CMs used in this work. Moreover, at very high catecholamine levels, iPSC-CMs 
showed a reduction in beating frequencies. This is in line with the publication of Paur et 
al., who showed that by activation of inhibitory Gi proteins, catecholamines can indeed 
lower the heart rate (Paur et al., 2012). Additionally, Heubach and colleagues showed that 
Epi can activate Gs and Gi proteins via β2-ARs, supporting the results observed (Heubach 
et al., 2004). Izumi and colleagues infused Epi in monkeys and observed apical dyskinesia 
(corresponding to electrical silencing) and an overall frequency increase (Izumi et al., 
2009). 
The observed field potential durations did increase under Iso stimulation and no difference 
between CTRL-iPSC-CMs and TTS-iPSC-CMs was found. The observed values are 
higher than in other reports using 25-day old hESC-iPSC-CMs (Zhu et al., 2017) with 300 
ms and 70-day-old human iPSC-CMs with 200 ms (Wells et al., 2019). In this work, neither 
relevant FPD prolongations nor significant differences in FPD between CTRL- and TTS-
iPSC-CMs were observed. TTS is associated with a QT-interval prolongation and 




2015; Ghadri et al., 2018b). However, not all TTS patients experience QT prolongation 
(Ghadri et al., 2018b; Templin et al., 2015).  
The absolute conduction speeds were 11.42 cm/s for CTRL-iPSC-CMs and 4.97 cm/s for 
TTS-iPSC-CMs, which differed significantly. The results are in the observed range of 
iPSC-CMs in culture, as shown by Zhu and colleagues, who reported a conduction velocity 
of 9 cm/s for 25-day-old and 12 cm/s for 28-day-old hESC-CMs (Zhu et al., 2017). Of note, 
the basal conduction velocity was reduced in TTS-iPSC-CMs compared to CTRL-iPSC-
CMs. This finding needs further confirmation due to the low n numbers and possible 
maturation differences between the two groups of iPSCs, which may have affected the 
conduction velocity. If this assumption is confirmed, conduction velocity differences might 
play a role in TTS in the form of conduction disturbances, blocks, or reentry events, which 
ultimately cause malignant ventricular arrhythmias, frequently observed in TTS patients 
(Bonello et al., 2008; Brown et al., 2015; Ghadri et al., 2018b).  
 
5.4 Differences in Ca2+ handling 
 
Overall, the results show Ca2+ handling differences between TTS-iPSC-CMs and CTRL-
iPSC-CMs on multiple levels. Despite increased rise times, Ca2+ handling was significantly 
faster under basal conditions with a significantly reduced T50 in TTS-iPSC-CMs compared 
to CTRL-iPSC-CMs.  
Upon Iso stimulation, T50 decreased by about 20% compared to basal levels. Comparing 
the results with other studies, the reduction in T50 times upon Iso stimulation is similar to 
the results found by Wu et al. in 60-day-old human iPSC-CMs, which was 20% after 1 µM 
Iso stimulation (Wu et al., 2015). It is also noteworthy that they showed that the T50 and 
rise times were differentiation dependent, with effects being stronger at shorter 
differentiation times (Wu et al., 2015). During acute TTS events, the SERCA protein level 
was reduced, causing an increased PLN/SERCA ratio (Nef et al., 2009b). This would 
result in slower T50 Ca2+ kinetics and contradict the observed low T50 times in TTS-iPSC-
CMs. The iPSC-CMs measured in this work did not have time to change protein 




observed stronger PLN-S16 phosphorylation under Iso stimulation in TTS-iPSC-CMs 
compared to CTRL-iPSC-CMs (Borchert et al., 2017). This would result in lower SERCA 
inhibition and consequently lower T50 times, which were observed. 
We found significantly higher rise times in TTS-iPSC-CMs than in CTRL-iPSC-CMs under 
basal conditions. There was no significant increase or decrease caused by Iso stimulation. 
This is in contrast to the aforementioned study of Wu and colleagues, which showed a 
reduction of time to peak times after Iso stimulation of iPSC-CMs by 20% (Wu et al., 2015). 
However, it must not go unmentioned that they used non-pacing experiments, whereas 
the data obtained here were from paced cardiomyocytes. 
In TTS-iPSC-CMs, an overall higher transient Ca2+ level was present at basal levels 
compared to CTRL-iPSC-CMs. In contrast to CTRL-iPSC-CMs, TTS-iPSC-CMs were not 
able to exhibit an increase in Ca2+ levels as a response to Iso. Furthermore, TTS-iPSC-
CMs transients shrank in response to high Iso dosages. This negative inotropic response 
(akinetic parts) is in line with the TTS phenotype (Templin et al., 2015). The observed 
behavior of transient shrinking in TTS-iPSC-CMs is in line with other studies showing that 
high Iso levels cause a decline in beating capacity and supports the theory of a dominant 
role of Gi proteins at high Iso levels in TTS (Paur et al., 2012). Surprisingly, the increased 
Ca2+ transients in TTS-iPSC-CMs without Iso stimulation did not result in stronger 
contraction force but resulted in the opposite: a reduction in force when challenged with 
higher Ca2+ concentrations in the medium in TTS-iPSC-EHM. It is worth mentioning that 
the CTRL-iPSC-CMs also exhibited a decrease of Ca2+ levels under high Iso stimulation 
compared to medium Iso levels (1 µM). This decrease, however, was smaller in 
comparison to TTS-iPSC-CMs. This underpins the theory of a higher vulnerability in TTS 
patients. 
The total Ca2+ leakage was not different between CTRL- and TTS-iPSC-CMs.  
 





When challenged with Iso, EHM constructed from TTS-iPSC-CMs showed a significantly 
higher sensitivity compared to CTRL-iPSC-EHM, as shown by a lower EC50. After 24 h 
Iso pre-stimulation, the observed EC50 differences were even higher than before, with 
CTRL-iPSC-EHM exhibiting a stronger EC50 increase than TTS-iPSC-EHM. Therefore, β-
AR desensitization upon Iso stimulation was present in both iPSC-EHM but stronger in 
CTRL-iPSC-EHMs. Additionally, beating frequency changes after 24 h Iso stimulation 
were higher in TTS-iPSC-EHM compared to CTRL-iPSC-EHM, which is in line with the 
reported frequency differences in the MEA measurements. Therefore, EHM 
measurements are in line with the previous findings suggesting a generally stronger 
reaction of TTS-iPSC-CMs towards Iso. The lower desensitization in TTS-iPSC-EHM is 
especially interesting. It is in line with the fact that many SNPs in β-ARs (Vriz et al., 2011; 
Zaroff et al., 2006) themselves or β-regulating proteins like GRK5 (Spinelli et al., 2010) 
were found. To put this in a whole picture: The high catecholamine levels seen in TTS 
patients (Wittstein et al., 2005), in combination with a disturbed shutdown of β-adrenergic 
signaling, could very well work together in a two-hit model to cause the disease. Nakano 
et al. recently published a study showing that GRK2 and β-arrestin were present at a high 
level in the cytoplasm and at the membrane of cardiomyocytes from TTS-patients (Nakano 
et al., 2018). They postulate that GRK2 and β-arrestin activity contributes to a Gs-to-Gi 
switch, which may contribute to the pathophysiology of TTS (Nakano et al., 2018).  
Interestingly, TTS-iPSC-EHMs showed a lower force development than CTRL-iPSC-EHM 
without catecholamine stimulation in response to rising medium Ca2+ levels. This is not in 
line with the increased F/F0 Ca2+ transients observed at basal levels in TTS-iPSC-CMs in 
comparison to CTRL-iPSC-CMs. 
 
5.6 CGP and ICI shed light on the role of different β-ARs  
 
Experiments with the selective β1-inhibitors CGP and selective β2-inhibitors ICI revealed 
that β2-ARs played a more important role in CTRL-iPSC-CMs, whereas β1-ARs were 
particularly engaged in TTS-iPSC-CMs, as judged from the MEA and Ca2+ experiments. 




measuring cAMP levels (Borchert et al., 2017). These measured effects are all associated 
with Gs activity. Since Paur et al. stressed the importance of Gi proteins in TTS (Paur et 
al., 2012), it would be of interest to check for Gs-to-Gi switch differences in CTRL- and 
TTS-iPSC-CMs in the future. It must be noted that the presence of CGP, ICI, or both was 
enough to cause significant changes in Ca2+ kinetics. Therefore, the analysis was done 
normalized T50 and rise times to exclude the effects of CGP or ICI. The different reactions 
towards CGP and ICI could, in principle, be caused by different β1- and β2-AR expression. 
Wu et al. found increasing β-AR expression in developing iPSC-CMs (Wu et al., 2015). 
They also found that β2-AR-expression was already upregulated in iPSC-CMs after 12 
days of culture, whereas β1-AR-expression kept increasing until iPSC-CMs reached day 
60. Therefore, the use of iPSC-CMs older than 2 months seems to be the right choice to 
achieve the proper expression of the two β-AR proteins. The combination of CGP and ICI 
greatly suppressed the response of iPSC-CMs towards Iso. This suggests that β1- and β2-
ARs are the main drivers of Iso reactions involved in the heart. The role of β3-ARs, which 
have been shown to have a negative effect on the heart contractility by nitric oxide and 
cGMP production (Gauthier et al., 1998) and might be cardioprotective (Cannavo and 
Koch, 2017) remains elusive and seems to be relatively small based on the CGP and ICI 
data. However, specific β3-AR-stimulation of CTRL- and TTS-iPSC-CMs could yield 
interesting results in the future. 
This complexity is supported by a different expression of β-ARs in the heart with a higher 
β1- to β2-AR ratio in ventricles than in atria (Steinfath et al., 1992). Both, the different β-
AR distribution and the complex 3D-form of the heart could be overcome by the use of 
cardiac organoids. Different β-responses can be caused by different CM microdomains, 
as demonstrated by Wright and colleagues, who found that basal CMs had more short-
lived cAMP responses to β2 stimulation (Wright et al., 2018). 
 
 





The different behavior of TTS-iPSC-CMs and CTRL-iPSC-CMs supports the theory of a 
genetic background of the disease. Whole-exome sequencing experiments, which were 
performed in cooperation with Prof. B. Wollnik (Human Genetics, UMG), found mutations 
in CASQ2 in the TTS5 patient (Borchert et al., 2017). This is the first study where CASQ2 
variants were suggested to be the genetic cause for the development of TTS. In support 
of a genetic origin, former studies described several mutations associated with TTS. Vriz 
et al. showed an association with variants in ADRB1 and ADRB2 (Vriz et al., 2011). 
Furthermore, variants of BAG3 resulting in reduced binding of miRNA-371a-5p (d’Avenia 
et al., 2015) and GRK5, which is known for β-AR desensitization (Liggett et al., 2008; 
Spinelli et al., 2010), have been linked to the development of TTS. In contrast to these 
findings, a recent case-control study showed a lack of association between TTS cases 
and mutations in ADRB1, BAG3, and GRK5 (Mattsson et al., 2018). Despite these 
incoherent observations, the different behaviors between TTS-iPSC-CMs and CTRL-
iPSC-CMs point towards a certain genetic predisposition. Indeed, Kumar et al. report a 
TTS family with a woman and her mother both suffering from TTS, while two reports 
described two sisters with TTS, further supporting the hypothesis that genetic factors may 
contribute to the etiology of the disease (Pison et al., 2004; Kumar et al., 2010; Ikutomi et 
al., 2014). However, until today TTS is not completely proven to be an inheritable 
condition. In light of the gathered data, one could theorize that, in principle, all humans 
are prone to getting TTS and the only distinction between TTS patients and non-patients 
might be some factors that lower the catecholamine threshold level for developing a TTS 
event. This is supported by the fact that all models used wildtype animals (Ali et al., 2020; 
Izumi et al., 2009; Paur et al., 2012) and a high catecholamine level is all that is needed 
to trigger a TTS phenotype. This can, of course, also be interpreted as a lack of genetic 
predisposition. The obtained results stress that CTRL- and TTS-iPSC-CMs behave 
differently and thereby suggest a genetic component in the disease. If a genetic 
predisposition exists, the aforementioned studies suggest that the nature of a 





5.8 TTS triggering catecholamine levels differ between 
models and patients 
 
Here in this study, we used catecholamine concentrations between 100 nM and 5 mM for 
2 h in most experiments. It is obvious that concentrations of 5 mM are supra-physiological. 
However, supraphysiological high amounts of catecholamines were also used in studies 
in rats and monkeys to trigger TTS-like events (Ali et al., 2020; Izumi et al., 2009; Paur et 
al., 2012). Izumi and colleagues, for example, used 10 µg/(min*kg) Epi infusion to trigger 
a TTS phenotype (Izumi et al., 2009), while Epi plasma levels during subacute TTS were 
reported to be 70 pg/ml (Christensen et al., 2016). The named studies show a rather 
strong response in the form of apical ballooning compared with the herein presented 
findings. The reasons for this could be the different species or the difference in the used 
models (in vivo vs. in vitro). Interestingly, TTS could be triggered in different animals, 
arguing for the theory that with high enough levels of catecholamines, TTS can indeed be 
triggered in any individual. Christensen et al. reported significantly increased plasma Epi 
levels in subacute TTS patients in the range from 70 pg/ml during the subacute phase and 
38 pg/mL during recovery in comparison to myocardial or endocarditis patients with similar 
symptoms having Epi levels of 44 pg/ml during subacute phase vs. 24 pg/ml during 
recovery (Christensen et al., 2016). Furthermore, the actual catecholamine levels during 
the onset of the TTS attack are largely unknown and may be higher than the levels 
measured in the hospital. It must be taken into careful consideration that blood 
catecholamine levels do not necessarily represent the catecholamine levels at the 
cardiomyocyte itself since direct sympathetic innervation is also present. Indeed, Kume et 
al. reported increased catecholamine release from sympathetic neurons in TTS cases 




Although this work uncovers some new insights into the pathology of TTS, there are 




Firstly, an iPSC-based system is, by its definition as it is not a naturally occurring cell type 
in the human body. Consequently, cells differentiated from this cell type may be different 
in several properties. ESCs, however, occur naturally with close similarities to iPSCs 
(Takahashi et al., 2007). Furthermore, the differentiation process from iPSCs to 
cardiomyocytes is, while related to the natural differentiation process, an artificial process, 
which is much shorter. It yields cardiomyocytes, which show significant differences to adult 
human cardiomyocytes. In fact, these cardiomyocytes are closer to embryonic 
cardiomyocytes than mature adult ones (Lundy et al., 2013). This may cause different 
results as TTS is a disease of the elderly. To obtain more mature cardiomyocytes, the 
approach of longer cultivation times (Lundy et al., 2013) and cultivation on a geltrex matrix 
(Parikh et al., 2017) was used in this work. Here, multinucleation, as a marker of 
maturation, was regularly observed in the iPSC-CMs. Synchronized electrical activity is 
another sign of maturation (Scuderi and Butcher, 2017), which was observed in the iPSC-
CMs used in this work. The iPSC-CMs showed conduction velocity, frequency increase 
towards catecholamines, and Ca2+ handling similar to iPSC-CMs used in other studies 
(Wells et al., 2019; Wu et al., 2015; Zhu et al., 2017). Further maturation indicators, such 
as the presence of a T-tubule network, would be a good addon for future maturation 
assessments. 
The main limitation of this investigation is that only a restricted number of cell isolates 
were tested. Thus, a much higher number of samples from both TTS patients and case-
matched controls are required to confirm these preliminary results. 
Another fact that needs mentioning is that a human heart does not consist of pure 
myocytes but rather a complex interplay between cardiomyocytes, fibroblasts, pacemaker 
cells, endothelial cells, and other cells organized in a complex 3D structure. Another point 
is obviously that a complex blood vessel system cannot be simulated in vitro yet. In 
consequence, the vasospasm component of TTS cannot be evaluated under cell culture 
conditions without proper vascularized 3D cell models. A future approach is the co-culture 
of iPSC-CMs and iPSC-derived neurons in 2D or heart brain-organoids. 
The influence of the heart-brain axis, which is important in TTS, cannot be modeled in a 




Another issue, which needs consideration is the percentage of different cardiac cell types 
yielded by the used differentiation protocol. While more than 80% of cells were cTnT 
positive, their exact type of iPSC-CM was not confirmed by patch-clamp. It is likely that 
some cells were of the atrial or nodal type, which could influence the results. By adapting 
protocols to obtain purer CM cell types, usage of pure ventricular CMs is possible in the 
future (Kolanowski et al., 2017; Weng et al., 2014). Furthermore, the reaction of atrial-
CMs could be studied as atria are sometimes affected in TTS and associated with a worse 
outcome (Eitel et al., 2011; Ghadri et al., 2018a). In addition, the use of multi-electrode 
arrays requires multiple preparation steps from digestion over the seeding of cells towards 
measuring, which may add to the complexity of this approach. Hopefully, with the advance 
of new materials and methods, this may be reduced in future experiments. Unfortunately, 
the available control probands were not as closely matched towards the TTS patients 
concerning the age as would have been desirable. Therefore, a future TTS-attack in the 
control probands cannot be excluded. However, it must be stated that optimal controls 
such as elderly women after menopause who went through very stressful events are not 
easy to obtain. This is a common problem when working with iPSCs. In future studies, 
better controls may be available due to a massive effort to build iPSC biobanks with a 
variety of probands. 
An additional challenge is the high levels of catecholamines, which are necessary to 
model the disease. In summary, it must be stated that there are still tremendous obstacles 
to be overcome to achieve a highly reproducible and reliable TTS model. 
 
5.10 Clinical implications 
 
As mentioned in the introduction, the role of β-blockers in TTS is controversial (Ghadri et 
al., 2018b; Isogai et al., 2016; Sharkey et al., 2010). In this work, most of the Iso effects 
were inhibited by a combination of CGP and ICI. This in line with studies showing β-
blockers to be effective in animal models (Izumi et al., 2009; Ueyama et al., 2002). It is 
worth to note that in our experimental setting with β-blockers, Iso was added after a pre-




patients, this is usually not the case as β-blockers are given after hospitalization. Following 
this logic, β-blockers should prevent further TTS attacks, however, this does not seem to 
be the case (Santoro et al., 2013). Another mystery is a possible association of TTS with 
cancer (Girardey et al., 2016; Sattler et al., 2017; Sattler et al., 2018). It is speculated that 
excessive catecholamine levels are associated with both diseases (Sattler et al., 2018). 
From this point of view, long-term Iso exposure of TTS-iPSCs could be of interest. This 
could also be connected to increased ROS levels followed by exposure to high 
catecholamines in TTS (El-Battrawy et al., 2018; Zhang et al., 2017) as ROS can also 
damage DNA and thus contribute towards cancer development. The used iPSC-CMs are, 
in principle, suited for ROS measurements, as demonstrated by Haupt et al. (Haupt et al., 
2020). Consequently, ROS measurements should be part of the model. As mentioned in 
the introduction, the presence of microvascular spasms is a very suitable theory to explain 
TTS (Abdelmoneim et al., 2009; Galiuto et al., 2010). This can, of course, not be modeled 
in the herein used model, as it would require complex and very well-defined organoids or 




From the targeted aims, the following could be achieved: 
A high number of CTRL- and TTS-iPSC were successfully reprogrammed and integration-
free reprogramming methods were established and optimized. The culture was switched 
towards feeder-free conditions to enhance reproducibility. Feeder-free differentiation to 
iPSC-CMs was successful and yielded high purity iPSC-CMs, which fulfilled some 
maturity criteria. In 2D culture, iPSC-CMs were treated with catecholamines and apoptotic 
analysis and Ca2+ imaging was established. MEA measurements were improved, 2D 
conduction velocity analysis was established and performed. Lipid measurements were 
optimized and carried out successfully. With the help of cooperation partners, 3D models 
in the form of iPSC-iPSC-EHM were produced and the impact of catecholamines on these 




and TTS-iPSC-CMs were explored. The overall produced model recapitulated some, but 




Future studies may further increase our knowledge of TTS. These could be done with the 
help of organoids creating a more natural environment. Furthermore, it may be worthwhile 
to study genetic predispositions underlying the disease. After model optimization, a high 
throughput drug screening would be possible to identify effective countermeasures 
against the effect of high concentrations of catecholamines. 
In addition, genetically engineered iPSC-CMs should be developed, which express only 
β1-, β2- or both AR types. The aforementioned different behaviors under specific 
pharmacological β1- or β2-stimulation support this approach. Another possible way is the 
use of explanted human hearts as cardiomyocyte source. This, however, has the 
drawback that cardiomyocytes from failing hearts are already pathologically degenerated 
and may therefore be of limited use. Another approach would be the exploration of TTS-
associated biomarkers, which has already started by the identification of certain miRNAs 
(Jaguszewski et al., 2014) to specifically differentiate TTS from a STEMI. While the model 
generated in this thesis focuses on rather short timescales, some TTS patients seem to 
show a longer timeframe to develop symptoms (Ghose and Banerjee, 2019; Stöllberger 
and Finsterer, 2019). These observations suggest a cumulative toxic effect of 
catecholamine. It is therefore of interest to know how the catecholamine levels of TTS 
patients develop over time and whether this has an influence on the length of the TTS-
attack. It is also interesting to know whether TTS patients have a generally higher level of 
catecholamines before disease onset. Considering the long-term elevated serum 
catecholamine levels (Christensen et al., 2016) in TTS patients after an event, this may 








Supplemental Figure 1: A: Normalized T50 measurements under Iso stimulation of all used 
CTRL-iPSC-CMs (2-C [n=47 cells], 3-C [n=67 cells], iFB2 [n=39 cells]). B: Normalized T50 
measurements under Iso stimulation of all used TTS-iPSC-CMs (2-TTS [n=26 cells], 5-TTS 







Supplemental Figure 2: A: Absolute T50 times without Iso stimulation of CTRL- (n=69 cells: 2-C 
[n=25 cells], 3-control [n=22 cells], iFB2 [n= 22 cells]) and TTS-iPSC-CMs (n=73 cells: 2-TTS 
[n=26 cells], 5-TTS [n=24 cells], 8-TTS [n= 23 cells]) under the influence of CGP/ICI/CGP+ICI. 
B: Absolute T50 times without Iso stimulation of CTRL- (n=69 cells: 2-C [n=25 cells], 3-C [n=22 
cells], iFB2 [n= 22 cells]) and TTS-iPSC-CMs (n=73 cells: 2-TTS [n=26 cells], 5-TTS [n=24 
cells], 8-TTS [n= 23 cells]) under the influence of CGP/ICI/CGP+ICI. Significances were 







Supplemental Figure 3: A: Spark frequency per cardiomyocyte for the single probands 2-C 
(n = 30 cells from 2 differentiations), 5-TTS (n = 30 from 2 differentiations), and 8-TTS (n = 27 
from 2 differentiations) B: FWHM per cardiomyocyte in the cell isolates from sample 2-C (n = 30 
cells from 2 differentiations), 5-TTS (n = 30 from 2 differentiations) and 8-TTS (n = 27 from 2 
differentiations)  C: FDHM frequency per cardiomyocyte from sample 2-C (n = 30 cells from 2 
differentiations), 5-TTS (n = 30 from 2 differentiations) and 8-TTS (n = 27 from 2 differentiations)  
D: Total calcium leak per cardiomyocyte as measured in 2-C (n = 30 cells from 2 differentiations), 
5-TTS (n = 30 from 2 differentiations) and 8-TTS (n = 27 from 2 differentiations). Differences were 
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